

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/12227 A1

(51) International Patent Classification⁷: **A61K 45/06, 31/505, 31/47 // (A61K 31/505, 31:19) (A61K 31/47, 31:19)**

(21) International Application Number: **PCT/US00/21021**

(22) International Filing Date: **2 August 2000 (02.08.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
09/373,261 12 August 1999 (12.08.1999) US

(71) Applicant: **AMERICAN CYANAMID COMPANY [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).**

(72) Inventors: **FROST, Philip; 4 Emerson Court, Morris Township, NJ 07960 (US). DISCAFANI-MARRO, Carolyn, Mary; 8 Brookside Avenue, Cortlandt Manor, NY 10567 (US).**

(74) Agents: **MILOWSKY, Arnold, S.; American Home Products Corporation, Patent Law Department - 2B, One Campus Drive, Parsippany, NJ 07054 et al. (US).**

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- *With international search report.*
- *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/12227 A1

(54) Title: NSAID AND EGFR KINASE INHIBITOR CONTAINING COMPOSITION FOR THE TREATMENT OR INHIBITION OF COLONIC POLYPS AND COLORECTAL CANCER

(57) Abstract: This invention provides a method of treating or inhibiting colonic polyps or treating or inhibiting colorectal cancer in a mammal in need thereof which comprises administering to said mammal an NSAID and an EGFR kinase inhibitor.

- 1 -

**NSAID AND EGFR KINASE INHIBITOR CONTAINING
COMPOSITION FOR THE TREATMENT INHIBITION OF
COLONIC POLYPS AND COLORECTAL CANCER**

5 This invention relates to the use of a combination of an NSAID and a epidermal growth factor receptor (EGFR) kinase inhibitor in the treatment and inhibition of colonic polyps and colorectal cancer.

Colonic Polyps occur in both a familial pattern (familial adenomatous polyposis; 10 FAP) and sporadically. FAP afflicts approximately 25,000 patients in the US; while it is estimated that sporadic adenomatous polyposis (SAP) occur in approximately 2 million people per year in the US alone. All these patients are at risk for developing adenocarcinoma of the colon. In the case of FAP, that risk is virtually 100% and these patients usually undergo a colectomy at an early age. Patients with sporadic 15 polyps are treated with polypectomy and require periodic colonoscopic examination because of their inherent risk of developing recurrent polyps. In fact, parents and siblings of these patients are also at increased risk for developing colorectal cancer.

The genetic basis for FAP has been linked to the presence of mutations in the APC gene. Similar APC mutations have been found in patients with sporadic polyposis. 20 Biochemically, the APC mutation occurs in conjunction with the increased expression of cyclooxygenase enzymes, particularly COX-2. These enzymes are essential for the production of prostaglandins, (prostaglandin's; (PG's)) that mediate a number of functions in the bowel including motility, vascular tone, angiogenesis and mucosal protection. PG's are also purported to discourage apoptosis and this is proposed as an 25 explanation for polyp formation.

The therapy of FAP and SAP has focused on inhibiting COX enzymes. Considerable evidence exists for the efficacy of COX inhibitors in reducing polyp formation. These COX inhibitors are predominantly NSAID's such as clinoril, sulindac, piroxicam and etodoloc, all of which appear to be equivalent in their action. 30 A major problem with NSAID therapy has been the development of serious side effects including peptic ulceration, and cholestatic hepatitis and renal papillary necrosis. Long term therapy with NSAIDs for the treatment of polyps is therefore considered to be impractical.

- 2 -

Protein tyrosine kinases are a class of enzymes that catalyze the transfer of a phosphate group from ATP or GTP to tyrosine residue located on protein substrates. Protein tyrosine kinases clearly play a role in normal cell growth. Many of the growth factor receptor proteins function as tyrosine kinases and it is by this process that they effect signaling. The interaction of growth factors with these receptors is a necessary event in normal regulation of cell growth. However, under certain conditions, as a result of either mutation or overexpression, these receptors can become deregulated; the result of which is uncontrolled cell proliferation which can lead to tumor growth and ultimately to the disease known as cancer [Wilks A.F., *Adv. Cancer Res.*, 60, 43 (1993) and Parsons, J.T.; Parsons, S.J., *Important Advances in Oncology*, DeVita V.T. Ed., J.B. Lippincott Co., Phila., 3 (1993)]. Among the growth factor receptor kinases and their proto-oncogenes that have been identified and which are targets of the compounds of this invention are the epidermal growth factor receptor kinase (EGF-R kinase, the protein product of the erbB oncogene), and the product produced by the erbB-2 (also referred to as the neu or HER2) oncogene. Since the phosphorylation event is a necessary signal for cell division to occur and since overexpressed or mutated kinases have been associated with cancer, an inhibitor of this event, a protein tyrosine kinase inhibitor, will have therapeutic value for the treatment of cancer and other diseases characterized by uncontrolled or abnormal cell growth. For example, overexpression of the receptor kinase product of the erbB-2 oncogene has been associated with human breast and ovarian cancers [Slamon, D. J., et. al., *Science*, 244, 707 (1989) and *Science*, 235, 1146 (1987)]. Deregulation of EGF-R kinase has been associated with epidermoid tumors [Reiss, M., et. al., *Cancer Res.*, 51, 6254 (1991)], breast tumors [Macias, A., et. al., *Anticancer Res.*, 7, 459 (1987)], and tumors involving other major organs [Gullick, W.J., *Brit. Med. Bull.*, 47, 87 (1991)]. Because of the importance of the role played by deregulated receptor kinases in the pathogenesis of cancer, many recent studies have dealt with the development of specific PTK inhibitors as potential anti-cancer therapeutic agents [some recent reviews: Burke, T.R., *Drugs Future*, 17, 119 (1992) and Chang, C.J.; Geahlen, R.L., *J. Nat. Prod.*, 55, 1529 (1992)].

It has recently been proposed that the activation and overexpression of COX-2 in adenomatous polyps is due to activation of the EGFR. EGFR stimulation by one of

- 3 -

it's ligands - amphiregulin (AR), induces the nuclear targeting of COX-2, release of PG's and subsequent mitogenesis, in polarized colonic epithelial cells. COX-2 inhibitors have been shown to prevent this series of events.

Colon cancer results from an accumulation of a number of genetic
5 abnormalities that occur over the lifetime of the developing tumor. The primary genetic change is a mutation in a gene called APC and this gene mutation occurs prior to the development of adenomas. Subsequent changes include mutations in the K-Ras, DCC and P53 genes as well as other changes that have not as yet been defined. What is known is that there is a clear progression from dysplastic cells within the
10 colon through early adenomas (polyps) to intermediate adenomas, late adenomas to carcinoma and its metastases.

There are a number of diseases that begin as polyps and progress to cancer. The best defined of these is FAP (familial adenomatous polyposis) which has a population incidence of 1 in 7,000. The APC mutation, or a mutation in a gene
15 associated with the function of APC, occurs in close to 100% of these patients. A similar occurrence of the APC mutation is present in sporadic adenomas and sporadic cancers. These adenomas occur with a population and incidence of 1 and 20.

DESCRIPTION OF THE INVENTION

20 This invention provides a method of treating or inhibiting colonic polyps or colorectal cancer in a mammal in need thereof, which comprises administering to said mammal an NSAID (including COX-1 and/or COX-2 inhibitors) and an EGFR kinase inhibitor.

The chemical structures of NSAIDs vary. Certain NSAIDs, such as
25 ketoprofen, fluribiorifen are aryl propionic acids, while others are cyclized derivatives of arylpropionic acids, arylacetic acids, thiazinecarboxamides, and the like. Preferred NSAIDs include, but are not limited to, ibuprofen, sulindac, ketoporfen, fenoprofen, flurbiprofen, naproxen, tiaprofenic acid, suprofen, etodolac, carprofen, ketrolac, piprofen, indoprofen, celecoxib, rofecoxib, mobicox, and benoxaprofen. The
30 NSAIDs of this invention are either commercially available or can be prepared by standard literature procedures.

For the purpose of defining the scope of this invention, an EGFR kinase inhibitor is defined as a molecule which inhibits the kinase domain of the EGFR. Compounds which are EGFR kinase inhibitors can readily be identified by one skilled

- 4 -

in the art using numerous methods, including the following standard pharmacological test procedure which measures the inhibition of the phosphorylation of the tyrosine residue of a peptide substrate catalyzed by EGFR kinase. Briefly, the peptide substrate (RR-SRC) has the sequence arg-arg-leu-ile-glu-asn-ala-glu-tyr-ala-ala-arg-gly. The enzyme is obtained as a membrane extract of A431 cells (American Type Culture Collection, Rockville, MD). A431 cells are grown in T175 flasks to 80% confluence. The cells are washed twice with phosphate buffered saline (PBS) without Ca²⁺. Flasks are rotated for 1.5 hours in 20 ml PBS with 1.0 mM ethylenediaminetetraacetic acid (EDTA) at room temperature and centrifuged at 600g for 10 minutes.

5 The cells are solubilized in 1 ml per 5 x 10⁶ cells of cold lysis buffer {10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.6, 10 mM NaCl, 2mM EDTA, 1mM phenylmethylsulfonyl-fluoride (PMSF), 10 mg/ml aprotinin, 10 mg/ml leupeptin, 0.1 mM sodium orthovanadate} in a Dounce homogenizer with 10 strokes on ice. The lysate is centrifuged at 600g for 10 minutes first to clear cell debris and

10 the supernatant further centrifuged at 100,000 g for 30 min at 4°C. The membrane pellet is suspended in 1.5 ml HNG buffer (50 mM HEPES, pH 7.6, 125 mM NaCl, 10% glycerol). The membrane extract is divided into aliquots, immediately frozen in liquid nitrogen and stored at -70°C.

15 The supernatant further centrifuged at 100,000 g for 30 min at 4°C. The membrane pellet is suspended in 1.5 ml HNG buffer (50 mM HEPES, pH 7.6, 125 mM NaCl, 10% glycerol). The membrane extract is divided into aliquots, immediately frozen in liquid nitrogen and stored at -70°C.

Compounds to be evaluated are made into 10 mg/ml stock solutions in 100% dimethylsulfoxide (DMSO). Prior to experiment, stock solutions are diluted to 500 mM with buffer (30 mM Hepes pH 7.4) and then serially diluted to the desired concentration.

An aliquot of the A431 membrane extract (10 mg/ml) is diluted in 30 mM HEPES (pH 7.4) to give a protein concentration of 50 ug/ml. To 4 μ l of enzyme preparation, EGF (1 μ l at 12 μ g/ml) is added and incubated for 10 min on ice followed by 4 μ l of the test compound or buffer; this mix is incubated on ice for 30 min. To this is added the ³³P-ATP (10 mCi/ml) diluted 1:10 in assay buffer along with the substrate peptide at a concentration of 0.5 mM (control reactions get no test compound) and the reaction is allowed to proceed for 30 min at 30°C. The reaction is stopped with 10% TCA and left on ice for at least 10 min after which tubes are microcentrifuged at full speed for 15 min. Then a portion of the supernatants are spotted on P81 phosphocellulose discs and washed twice in 1% acetic acid then water for 5 min each followed by scintillation counting. The results obtained can be expressed as an IC₅₀. The IC₅₀ is the concentration of test compound needed to reduce the total amount of phosphorylated substrate by 50%. The % inhibition of the test compound is determined for at least three different concentrations and the IC₅₀

- 5 -

value is evaluated from the dose response curve. The % inhibition is evaluated with the following formula:

$$\% \text{ inhibition} = 100 - [\text{CPM(drug)}/\text{CPM(control)}] \times 100$$


5 where CPM(drug) is in units of counts per minute and is a number expressing the amount of radiolabeled ATP ($\text{g-}^{33}\text{P}$) incorporated onto the RR-SRC peptide substrate by the enzyme after 30 minutes at 30°C in the presence of test compound as measured by liquid scintillation counting. CPM(control) is in units of counts per minute and is a
10 number expressing the amount of radiolabeled ATP ($\text{g-}^{33}\text{P}$) incorporated into the RR-SRC peptide substrate by the enzyme after 30 minutes at 30°C in the absence of test compound as measured by liquid scintillation counting. The CPM values are corrected for the background counts produced by ATP in the absence of the enzymatic reaction. Compounds having an IC₅₀ of 200 nM or less are considered to
15 be significantly active EGFR kinase inhibitors.

It is preferred that the EGFR kinase inhibitor irreversibly inhibits EGFR kinase, typically by possessing a reactive moiety (such as a Michael acceptor) which can form a covalent bond with EGFR.

20

More preferred EGFR kinase inhibitors include the following:

A. Quinazolines of Formula 1, which are disclosed in US Patent 5,760,041, and PCT Patent Application Publication WO 99/09016. These compounds can be
25 prepared according to the methodology described in US Patent 5,760,041, which is hereby incorporated by reference. The structure of the EGFR kinase inhibitors of Formula 1 are as follows:



30

- 6 -

wherein:

- X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminomethyl, N-alkylaminomethyl of 2-7 carbon atoms, N,N-dialkylaminomethyl of 3-7 carbon atoms, mercapto, methylmercapto, and benzoylamino;
- Z is -NH-, -O-, -S-, or -NR-;
- 20 R is alkyl of 1-6 carbon atoms, or carboalkyl of 2-7 carbon atoms;
R₁, R₃, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyoxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms;
- 25
- 30
- 35

- 7 -

atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino,

$R_7-(C(R_6)_2)_g-Y-$, $R_7-(C(R_6)_2)_p-M-(C(R_6)_2)_k-Y-$, or Het-W-(C(R₆)₂)_k-Y-


5

Y is a divalent radical selected from the group consisting of


$-(CH_2)_a-$, $-O-$, and $-N_{R_6}-$;

- 10 R_7 is $-NR_6R_6$, or $-OR_6$;
 M is $>NR_6$, $-O-$, $>N-(C(R_6)_2)_pNR_6R_6$, or $>N-(C(R_6)_2)_p-OR_6$;
 W is $>NR_6$, $-O-$ or is a bond;
 Het is a heterocycle, optionally mono- or di-substituted on carbon or nitrogen with R_6 and optionally mono-substituted on carbon with $-CH_2OR_6$; wherein the
- 15 heterocycle is selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine, aziridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, piperazine, tetrahydrofuran, and tetrahydropyran;
- 20 R_6 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl (2-7 carbon atoms), phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms;
- 25
- 30 R_2 , is selected from the group consisting of



- 8 -



- 9 -



5 R_5 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6
carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,



10 R_8 , and R_9 are each, independently, $-(C(R_6)_2)_rNR_6R_6$, or $-(C(R_6)_2)_rOR_6$;

J is independently hydrogen, chlorine, fluorine, or bromine;

Q is alkyl of 1-6 carbon atoms or hydrogen;

a = 0 or 1;

15 g = 1-6;

k = 0-4;

n is 0-1;

p = 2-4;

q = 0-4;

20 r = 1-4;

s = 1-6;

- 10 -

$u = 0-4$ and $v = 0-4$, wherein the sum of $u+v$ is 2-4;
or a pharmaceutically acceptable salt thereof.

With respect to the quinazolines of Formula 1, the pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: acetic, lactic, citric, tartaric, succinic, maleic, malonic, gluconic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids.

The alkyl portion of the alkyl, alkoxy, alkanoyloxy, alkoxymethyl, alkanoyloxymethyl, alkylsulphanyl, alkylsulphonyl, alkylsulfonamido, carboalkoxy, carboalkyl, carboxyalkyl, carboalkoxyalkyl, alkanoylamino, N-alkylcarbamoyl, and N,N-dialkylcarbamoyl substituents include both straight chain as well as branched carbon chains. The alkenyl portion of the alkenyl, alkenoyloxymethyl, alkenyloxy, alkenylsulfonamido, substituents include both straight chain as well as branched carbon chains and one or more sites of unsaturation. The alkynyl portion of the alkynyl, alkynoyloxymethyl, alkynylsulfonamido, alkynyoxy, substituents include both straight chain as well as branched carbon chains and one or more sites of unsaturation. Carboxy is defined as a $\cdot\text{CO}_2\text{H}$ radical. Carboalkoxy of 2-7 carbon atoms is defined as a $\cdot\text{CO}_2\text{R}''$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Carboxyalkyl is defined as a $\text{HO}_2\text{C}-\text{R}'''$ - radical where R''' is a divalent alkyl radical of 1-6 carbon atoms. Carboalkoxyalkyl is defined as a $\text{R}''\text{O}_2\text{C}-\text{R}'''$ - radical where R''' is a divalent alkyl radical and where R'' and R''' together have 2-7 carbon atoms. Carboalkyl is defined as a $\cdot\text{COR}''$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkanoyloxy is defined as a $\cdot\text{OCOR}''$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkanoyloxymethyl is defined as $\text{R}''\text{CO}_2\text{CH}_2\cdot$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkoxymethyl is defined as $\text{R}''\text{OCH}_2\cdot$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkylsulphanyl is defined as $\text{R}''\text{SO}\cdot$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkylsulphonyl is defined as $\text{R}''\text{SO}_2\cdot$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkylsulfonamido, alkenylsulfonamido, alkynylsulfonamido are defined as $\text{R}''\text{SO}_2\text{NH}\cdot$ radical, where R'' is an alkyl radical of 1-6 carbon atoms, an alkenyl radical of 2-6 carbon atoms, or an alkynyl radical of 2-6 carbon atoms, respectively. N-alkylcarbamoyl is defined as $\text{R}''\text{NHCO}\cdot$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. N,N-dialkylcarbamoyl is defined as $\text{R}''\text{R}'\text{NCO}\cdot$ radical, where R'' is an alkyl radical of 1-6 carbon atoms, R' is an alkyl radical of 1-6 carbon atoms and R' , and R'' may be the same or different. When X is substituted, it is preferred that it is mono-, di-, or tri-substituted, with monosubstituted being most

- 11 -


preferred. It is preferred that of the substituents R1, R3, and R4, at least one is hydrogen and it is most preferred that two or three be hydrogen. It is also preferred that X is a phenyl ring, Z is -NH-, and n = 0.

Het is a heterocycle, as defined above which may be optionally mono- or di-substituted with R₆ on carbon or nitrogen and optionally mono-substituted on carbon with -CH₂OR₆. Het may be bonded to W via a carbon atom on the heterocyclic ring, or when Het is a nitrogen containing heterocycle which also contains a saturated carbon-nitrogen bond, such heterocycle may be bonded to W, via the nitrogen when W is a bond. When Het is substituted with R₆, such substitution may be on a ring 10 carbon, or in the case of a nitrogen containing heterocycle, which also contains a saturated carbon-nitrogen, such nitrogen may be substituted with R₆. Preferred substituted heterocycles include 2,6-disubstituted morpholine, 2,5-disubstituted thiomorpholine, 2-substituted imidazole, N-substituted 1,4-piperazine, N-substituted piperadine, and N-substituted pyrrolidine.

15 The compounds of Formula 1 may contain one or more asymmetric carbon atoms; in such cases, the compounds of Formula 1 cover the individual diastereomers, the racemates, and the individual R and S enantiomers thereof.

20 B. Cyanoquinolines of Formula 2, which are disclosed in US Patent 6,002,008, and PCT Patent Application Publication WO 98/43960. These compounds can be prepared according to the methodology described in US Patent 6,002,008 which is hereby incorporated by reference. The structure of the EGFR kinase inhibitors of Formula 2 are as follows:

25



2

wherein:

- 12 -

X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxylalkyl of 1-6 carbon atoms, halomethyl, alkoxyymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino;





15 n is 0-1;

Y is -NH-, -O-, -S-, or -NR- ;



R is alkyl of 1-6 carbon atoms;

R₁, R₂, R₃, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyoxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9 carbon atoms, alkoxyymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, aminoalkyl of 1-4 carbon atoms, N-alkylaminoalkyl of 2-7 carbon atoms, N,N-dialkylaminoalkyl of 3-14 carbon atoms, phenylamino, benzylamino,

- 13 -



5



R₅ is alkyl of 1-6 carbon atoms, alkyl optionally substituted with one or more halogen atoms, phenyl, or phenyl optionally substituted with one or more halogen, 10 alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, nitro, cyano, or alkyl of 1-6 carbon atoms groups;

R₆ is hydrogen, alkyl of 1-6 carbon atoms, or alkenyl of 2-6 carbon atoms;

R₇ is chloro or bromo

- 14 -

- R₈ is hydrogen, alkyl of 1-6 carbon atoms, aminoalkyl of 1-6 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-12 carbon atoms, N-cycloalkylaminoalkyl of 4-12 carbon atoms, N-cycloalkyl-N-alkylaminoalkyl of 5-18 carbon atoms, N,N-dicycloalkylaminoalkyl of 7-18 carbon atoms, morpholino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, piperidino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, N-alkyl-piperidino-N-alkyl wherein either alkyl group is 1-6 carbon atoms, azacycloalkyl-N-alkyl of 3-11 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-8 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms, chloro, fluoro, or bromo;
- 5 Z is amino, hydroxy, alkoxy of 1-6 carbon atoms, alkylamino wherein the alkyl moiety is of 1-6 carbon atoms, dialkylamino wherein each of the alkyl moieties is of 1-6 carbon atoms, morpholino, piperazino, N-alkylpiperazino wherein the alkyl moiety is of 1-6 carbon atoms, or pyrrolidino;
- 10 15 m = 1-4, q = 1-3, and p = 0-3; any of the substituents R₁, R₂, R₃, or R₄ that are located on contiguous carbon atoms can together be the divalent radical -O-C(R₈)₂-O-; or a pharmaceutically acceptable salt thereof with the proviso that when Y is -NH-, R₁, R₂, R₃, and R₄ are hydrogen, and n is 0, X is not 2-methylphenyl.
- 20 25 With respect to the cyanoquilines of Formula 2, the pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: acetic, lactic, citric, tartaric, succinic, maleic, malonic, gluconic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids.
- 30 35 The alkyl portion of the alkyl, alkoxy, alkanoyloxy, alkoxymethyl, alkanoyloxymethyl, alkylsulphanyl, alkylsulphonyl, alkylsulfonamido, carboalkoxy, carboalkyl, alkanoylamino aminoalkyl, alkylaminoalkyl, N,N-dicycloalkylaminoalkyl, hydroxyalkyl, and alkoxyalkyl substituents include both straight chain as well as branched carbon chains. The cycloalkyl portions of N-cycloalkyl-N-alkylaminoalkyl and N,N-dicycloalkylaminoalkyl substituents include both simple carbocycles as well as carbocycles containing alkyl substituents. The alkenyl portion of the alkenyl, alkenoyloxymethyl, alkenyloxy, alkenylsulfonamido, substituents include both straight chain as well as branched carbon chains and one or more sites of unsaturation. The alkynyl portion of the alkynyl, alkynoyloxymethyl, alkynylsulfonamido, alkynyloxy, substituents include both straight chain as well as branched

- 15 -

carbon chains and one or more sites of unsaturation. Carboxy is defined as a $\text{-CO}_2\text{H}$ radical. Carboalkoxy of 2-7 carbon atoms is defined as a $\text{-CO}_2\text{R}''$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Carboalkyl is defined as a $\text{-COR}''$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkanoyloxy is defined as a 5 $\text{-OCOR}''$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkanoyloxymethyl is defined as $\text{R}''\text{CO}_2\text{CH}_2\text{-}$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkoxy methyl is defined as $\text{R}''\text{OCH}_2\text{-}$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkylsulphinyl is defined as $\text{R}''\text{SO-}$ radical, where 10 R'' is an alkyl radical of 1-6 carbon atoms. Alkylsulphonyl is defined as $\text{R}''\text{SO}_2-$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkylsulfonamido, alkenylsulfonamido, alkynylsulfonamido are defined as $\text{R}''\text{SO}_2\text{NH-}$ radical, where R'' is an alkyl radical of 1-6 carbon atoms, an alkenyl radical of 2-6 carbon atoms, or an 15 alkynyl radical of 2-6 carbon atoms, respectively. N-alkylcarbamoyl is defined as $\text{R}''\text{NHCO-}$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. N,N-dialkylcarbamoyl is defined as $\text{R}''\text{R}'\text{NCO-}$ radical, where R'' is an alkyl radical of 1-6 carbon atoms, R' is an alkyl radical of 1-6 carbon atoms and R' , and R'' may be the same or different. When X is substituted, it is preferred that it is mono-, di-, or tri-substituted, with monosubstituted being most preferred. It is preferred that of the substituents R_1 , R_2 , R_3 , and R_4 , at least one is hydrogen and it is most preferred that 20 two or three be hydrogen. An azacycloalkyl-N-alkyl substituent refers to a monocyclic heterocycle that contains a nitrogen atom on which is substituted a straight or branched chain alkyl radical. A morpholino-N-alkyl substituent is a morpholine ring substituted on the nitrogen atom with a straight or branch chain alkyl radical. A piperidino-N-alkyl substituent is a piperidine ring substituted on one 25 of the nitrogen atoms with a straight or branch chain alkyl radical. A N-alkyl-piperidino-N-alkyl substituent is a piperidine ring substituted on one of the nitrogen atoms with a straight or branched chain alkyl group and on the other nitrogen atom with a straight or branch chain alkyl radical.


The compounds of Formula 2 may contain an asymmetric carbon; in such 30 cases, the compounds of Formula 2 cover the racemate and the individual R and S enantiomers, and in the case were more than one asymmetric carbon exists, the individual diasteromers, their racemates and individual enantiomers.

35 C. Cyanoquinolines of Formula 3, which are disclosed in PCT Patent Application Publication WO 00/18761. These compounds can be prepared according to the

- 16 -

methodology described in US Patent 6,002,008, and PCT Patent Application Publication WO 00/18761, which are hereby incorporated by reference. The structure of the EGFR kinase inhibitors of Formula 3 are as follows:

5



3

wherein:

X is a bicyclic aryl or bicyclic heteroaryl ring system of 8 to 12 atoms where the
 10 bicyclic heteroaryl ring contains 1 to 4 heteroatoms selected from N, O, and S with the proviso that the bicyclic heteroaryl ring does not contain O-O, S-S, or S-O bonds and where the bicyclic aryl or bicyclic heteroaryl ring may be optionally mono-, di-, tri, or tetra-substituted with a substituent selected from the group consisting of halogen, oxo, thio, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino; or
 15
 20
 25

- 17 -

X is a radical radical having the formula:



wherein A is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono- or di-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino;

T is bonded to a carbon of A and is:

- 20 - NH(CH₂)_m-, -O(CH₂)_m-, -S(CH₂)_m-, -NR(CH₂)_m-, -(CH₂)_m-

-(CH₂)_mNH-, -(CH₂)_mO-, -(CH₂)_mS-, or -(CH₂)_mNR-;


L is an unsubstituted phenyl ring or a phenyl ring mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms,

- 18 -

- carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino; 5 provided that L can be an unsubstituted phenyl ring only when m > 0 and T is not -CH₂NH- or -CH₂O-; or
- L is a 5- or 6-membered heteroaryl ring where the heteroaryl ring contains 1 to 3 heteroatoms selected from N, O, and S, with the proviso that the heteroaryl ring does not contain O-O, S-S, or S-O bonds, and where the heteroaryl ring is 10 optionally mono- or di-substituted with a substituent selected from the group consisting of halogen, oxo, thio, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxyethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, 15 hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, 20 carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino;
- 25 Z is -NH-, -O-, -S-, or -NR- ;
- R is alkyl of 1-6 carbon atoms, or carboalkyl of 2-7 carbon atoms;
- G₁, G₂, R₁, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyoxy of 2-6 carbon atoms, hydroxymethyl, 30 halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9 carbon atoms, alkoxyethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms,

- 19 -

alkylthio of 1-6 carbon atoms, alkylsulphanyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, trifluoromethoxy, cyano, nitro, carboxy, 5 carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-N-alkenylamino of 10 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino,




15 $R_7-(C(R_6)_2)_q-Y-$, $R_7-(C(R_6)_2)_p-M-(C(R_6)_2)_k-Y-$, or $Het-(C(R_6)_2)_q-W-(C(R_6)_2)_k-Y-$;

or R_1 and R_4 are as defined above and G_1 or G_2 or both are

R_2-NH- ;

20 or if any of the substituents R_1 , G_2 , G_3 , or R_4 are located on contiguous carbon atoms then they may be taken together as the divalent radical
 $-O-C(R_6)_2-O-$;

Y is a divalent radical selected from the group consisting of



25


R_7 is $-NR_6R_6$, $-OR_6$, $-J$, $-N(R_6)_3$, or $-NR_6(OR_6)$;

M is $>NR_6$, $-O-$, $>N-(C(R_6)_2)_pNR_6R_6$, or $>N-(C(R_6)_2)_p-OR_6$;

W is $>NR_6$, $-O-$ or is a bond;

- 20 -


Het is selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine, aziridine, pyridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, thiazole, thiazolidine, tetrazole, piperazine, furan, thiophene, tetrahydrothiophene,




- 5 tetrahydrofuran, dioxane, 1,3-dioxolane, tetrahydropyran, and ;
 wherein Het is optionally mono- or di-substituted on carbon or nitrogen with R₆, optionally mono- or di-substituted on carbon with hydroxy, -N(R₆)₂, or -OR₆, optionally mono or di-substituted on carbon with the mono-valent radicals -(C(R₆)₂)_sOR₆ or -(C(R₆)₂)_sN(R₆)₂, and optionally mono or di-
 10 substituted on a saturated carbon with divalent radicals -O- or -O(C(R₆)₂)_sO-;

- R₆ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl (2-7 carbon atoms), phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms; with the proviso that the alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;
- 25 R₂, is selected from the group consisting of



- 21 -



- 22 -




R3 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of
 5 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,



10

R5 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of
 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,



- 23 -



R_8 , and R_9 are each, independently, $-(C(R_6)_2)_rNR_6R_6$, or $-(C(R_6)_2)_rOR_6$;

5

J is independently hydrogen, chlorine, fluorine, or bromine;

Q is alkyl of 1-6 carbon atoms or hydrogen;

$a = 0$ or 1 ;

$g = 1\text{-}6$;

10 $k = 0\text{-}4$;

n is $0\text{-}1$;

m is $0\text{-}3$;

$p = 2\text{-}4$;

$q = 0\text{-}4$;

15 $r = 1\text{-}4$;

$s = 1\text{-}6$;

$u = 0\text{-}4$ and $v = 0\text{-}4$, wherein the sum of $u+v$ is $2\text{-}4$;

or a pharmaceutically acceptable salt thereof,

provided that

20 when R_6 is alkenyl of 2-7 carbon atoms or alkynyl of 2-7 carbon atoms, such alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;

and further provided that

when Y is $-NR_6-$ and R_7 is $-NR_6R_6$, $-N(R_6)_3^+$, or $-NR_6(OR_6)$, then $g = 2\text{-}6$;

25 when M is $-O-$ and R_7 is $-OR_6$ then $p = 1\text{-}4$;

when Y is $-NR_6-$ then $k = 2\text{-}4$;

when Y is $-O-$ and M or W is $-O-$ then $k = 1\text{-}4$

when W is not a bond with Het bonded through a nitrogen atom then $q = 2\text{-}4$

- 24 -

and when W is a bond with Het bonded through a nitrogen atom and Y is -O- or -NR₆- then k = 2-4.

With respect to the cyanoquinolines of Formula 3, the pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: acetic, lactic, citric, tartaric, succinic, maleic, malonic, gluconic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids.

Preferred bicyclic aryl or bicyclic heteroaryl ring systems include naphthalene, 1,2,3,4-tetrahydronaphthalene, indane, 1-oxo-indane, 1,2,3,4-tetrahydroquinoline, naphthyridine, benzofuran, 3-oxo-1,3-dihydro-isobenzofuran, benzothiaphene, 1,1-dioxo-benzothiaphene, indole, 2,3-dihydroindole, 1,3-dioxo-2,3-dihydro-1H-isoindole, benzotriazole, 1H-indazole, indoline, benzopyrazole, 1,3-benzodioxole, benzooxazole, purine, phthalimide, coumarin, chromone, quinoline, tetrahydroquinoline, isoquinoline, benzimidazole, quinazoline, pyrido[2,3-b]pyridine, pyrido[3,4-b]pyrazine, pyrido[3,2-c]pyridazine, pyrido[3,4-b]pyridine, 1H-pyrazole-[3,4-d]pyrimidine, 1,4-benzodioxane, pteridine, 2(1H)-quinolone, 1(2H)-isoquinolone, 2-oxo-2,3-dihydro-benzthiazole, 1,2-methylenedioxybenzene, 2-oxindole, 1,4-benzisoxazine, benzothiazole, quinoxaline, quinoline-N-oxide, isoquinoline-N-oxide, quinoxaline-N-oxide, quinazoline-N-oxide, benzoazine, phthalazine, 1,4-dioxo-1,2,3,4-tetrahydro-phthalazine, 2-oxo-1,2-dihydro-quinoline, 2,4-dioxo-1,4-dihydro-2H-benzo[d][1,3]oxazine, 2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]-diazepine, or cinnoline.

When L is a 5 or 6-membered heteroaryl ring, preferred heteroaryl rings include pyridine, pyrimidine, imidazole, thiazole, thiazolidine, pyrrole, furan, thiophene, oxazole, or 1,2,4-triazole.

Either or both rings of the bicyclic aryl or bicyclic heteroaryl group may be fully unsaturated, partially saturated, or fully saturated. An oxo substituent on the bicyclic aryl or bicyclic heteroaryl moiety means that one of the carbon atoms has a carbonyl group. An thio substituent on the bicyclic aryl or bicyclic heteroaryl moiety means that one of the carbon atoms has a thiocarbonyl group.

When L is a 5 or 6-membered heteroaryl ring, it may be fully unsaturated, partially saturated, or fully saturated. The heteroaryl ring can be bound to A via carbon or nitrogen. An oxo substituent on the heteroaryl ring means that one of the

- 25 -

carbon atoms has a carbonyl group. An thio substituent on the heteroaryl ring means that one of the carbon atoms has a thiocarbonyl group.

The alkyl portion of the alkyl, alkoxy, alkanoyloxy, alkoxymethyl, alkanoyloxymethyl, alkylsulphiny, alkylsulphonyl, alkylsulfonamido, carboalkoxy, 5 carboalkyl, carboxyalkyl, carboalkoxyalkyl, alkanoylamino, N-alkylcarbamoyl, and N,N-dialkylcarbamoyl , N-alkylaminoalkoxy, N,N-dialkylaminoalkoxy include both straight chain as well as branched carbon chains. The alkenyl portion of the alkenyl, alkenoyloxymethyl, alkenyloxy, alkenylsulfonamido, substituents include both straight chain as well as branched carbon chains and one or more sites of unsaturation 10 and all possible configurational isomers. The alkynyl portion of the alkynyl, alkynoyloxymethyl, alkynylsulfonamido, alkynyoxy, substituents include both straight chain as well as branched carbon chains and one or more sites of unsaturation. Carboxy is defined as a -CO₂H radical. Carboalkoxy of 2-7 carbon atoms is defined as a -CO₂R" radical, where R" is an alkyl radical of 1-6 carbon atoms. Carboxyalkyl 15 is defined as a HO₂C-R"- radical where R" is a divalent alkyl radical of 1-6 carbon atoms. Carboalkoxyalkyl is defined as a R"O₂C-R"- radical where R" is a divalent alkyl radical and where R" and R" together have 2-7 carbon atoms. Carboalkyl is defined as a -COR" radical, where R" is an alkyl radical of 1-6 carbon atoms. Alkanoyloxy is defined as a -OCOR" radical, where R" is an alkyl radical of 1-6 20 carbon atoms. Alkanoyloxymethyl is defined as R"CO₂CH₂- radical, where R" is an alkyl radical of 1-6 carbon atoms. Alkoxymethyl is defined as R"OCH₂- radical, where R" is an alkyl radical of 1-6 carbon atoms. Alkylsulphiny is defined as R"SO- radical, where R" is an alkyl radical of 1-6 carbon atoms. Alkylsulphonyl is defined as R"SO₂- radical, where R" is an alkyl radical of 1-6 carbon atoms. Alkylsulfonamido, 25 alkenylsulfonamido, alkynylsulfonamido are defined as R"SO₂NH- radical, where R" is an alkyl radical of 1-6 carbon atoms, an alkenyl radical of 2-6 carbon atoms, or an alkynyl radical of 2-6 carbon atoms, respectively. N-alkylcarbamoyl is defined as R"NHCO- radical, where R" is an alkyl radical of 1-6 carbon atoms. N,N-dialkylcarbamoyl is defined as R"RNCO- radical, where R" is an alkyl radical of 1-6 30 carbon atoms, R' is an alkyl radical of 1-6 carbon atoms and R', and R" may be the same or different . When X is substituted, it is preferred that it is mono- , di- , or tri-substituted, with monosubstituted being most preferred. It is preferred that of the

- 26 -

substituents R1 and R4, at least one is hydrogen and it is most preferred that both be hydrogen. It is also preferred that X is a phenyl ring, Z is -NH-, and n = 0.


Het is a heterocycle, as defined above which may be optionally mono- or di-substituted with R₆ on carbon or nitrogen, optionally mono- or di-substituted on 5 carbon with hydroxy, -N(R₆)₂, or -OR₆, optionally mono or di-substituted on carbon with -(C(R₆)₂)_sOR₆ or -(C(R₆)₂)_sN(R₆)₂, and optionally mono or di-substituted on a saturated carbon with divalent -O- or -O(C(R₆)₂)_sO- (carbonyl and ketal groups , respectively); in some cases when Het is substituted with -O- (carbonyl), the carbonyl group can be hydrated. Het may be bonded to W when q = 0 10 via a carbon atom on the heterocyclic ring, or when Het is a nitrogen containing heterocycle which also contains a saturated carbon-nitrogen bond, such heterocycle may be bonded to carbon, via the nitrogen when W is a bond. When q = 0 and Het is a nitrogen containing heterocycle which also contains an unsaturated carbon-nitrogen bond, that nitrogen atom of the heterocycle may be bonded to carbon when W is a 15 bond and the resulting heterocycle will bear a positive charge. When Het is substituted with R₆, such substitution may be on a ring carbon, or in the case of a nitrogen containing heterocycle, which also contains a saturated carbon-nitrogen, such nitrogen may be substituted with R₆ or in the case of a nitrogen containing heterocycle, which also contains an unsaturated carbon-nitrogen, such nitrogen may 20 be substituted with R₆ in with case the heterocycle will bear a positive charge.

Preferred heterocycles include pyridine, 2,6-disubstituted morpholine, 2,5-disubstituted thiomorpholine, 2-substituted imidazole, substituted thiazole, N-substituted imidazole, N-substituted 1,4-piperazine, N-substituted piperidine, and N-substituted pyrrolidine.

25 The compounds of Formula 3 may contain one or more asymmetric carbons atoms; in such cases, the compounds of Formula 3 include the individual diasteromers, the racemates, and the individual R and S enantiomers thereof. Some of the compound of this invention may contain one or more double bonds; in such cases, the compounds of this invention include each of the possible configurational isomers 30 as well as mixtures of these isomers.

- 27 -

D. Cyanoquinolines of Formula 4, which are disclosed in PCT Patent Application Publication WO 00/18740. These compounds can be prepared according to the methodology described in US Patent 6,002,008, and PCT Patent Application Publication WO 00/18740, which are hereby incorporated by reference. The structure 5 of the EGFR kinase inhibitors of Formula 4 are as follows:



10 wherein:

X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-, di-, or tri-substituted with a substituent selected from the 15 group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 20 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino;

- 28 -

Z is -NH-, -O-, -S-, or -NR- ;

R is alkyl of 1-6 carbon atoms, or carboalkyl of 2-7 carbon atoms;



G₁, G₂, R₁, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy

5 of 2-6 carbon atoms, alkynyoxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9

10 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, trifluoromethoxy, cyano, nitro, carboxy,

15 carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino,


20




with the proviso that either G₁ or G₂ or both G₁ and G₂ must be a radical selected from the group

25

- 29 -



Y is a divalent radical selected from the group consisting of



5


R₇ is -NR₆R₆, -J, -OR₆, -N(R₆)₃⁺, or -NR₆(OR₆);

10 R'7 is -NR₆(OR₆), -N(R₆)₃⁺, alkoxy of 1-6 carbon atoms, alkynoxy of 1-6 carbon atoms, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, N-alkyl-N-alkynylamino of 4 to 12 carbon atoms, N-alkenyl-N-alkynylamino of 4 to 12 carbon atoms, or N,N-dialkynylamino of 6-12 carbon atoms with the proviso that the alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;

M is >NR₆, -O-, >N-(C(R₆)₂)_pNR₆R₆, or >N-(C(R₆)₂)_p-OR₆;

W is >NR₆, -O- or is a bond;

15 Het is a heterocycle selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine, aziridine, pyridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, thiazole, thiazolidine, tetrazole, piperazine, furan, thiophene, tetrahydrothiophene, tetrahydrofuran, dioxane, 1,3-dioxolane, tetrahydro-

20 pyran, and  ; wherein the heterocycle is optionally mono- or di-substituted on carbon or nitrogen with R₆, optionally mono- or di-substituted on carbon with hydroxy,

- 30 -

-N(R₆)₂, or -OR₆, optionally mono or di-substituted on carbon with the mono-valent radicals -(C(R₆)₂)_sOR₆ or -(C(R₆)₂)_sN(R₆)₂, or optionally mono or di-substituted on a saturated carbon with divalent radicals -O- or -O(C(R₆)₂)_sO-;

5


R₆ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl (2-7 carbon atoms), phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms;

10


15

R₂, is selected from the group consisting of


- 31 -




- 32 -



R₃ is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of
 5 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,





with the proviso that at least one of the R₃ groups is selected from the group
 10



- 33 -

R₅ is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,



5

R₈, and R₉ are each, independently, -(C(R₆)₂)_rNR₆R₆, or -(C(R₆)₂)_rOR₆;

J is independently hydrogen, chlorine, fluorine, or bromine;

10 Q is alkyl of 1-6 carbon atoms or hydrogen;

a = 0 or 1;

g = 1-6;

k = 0-4;

n is 0-1;

15 p = 2-4;

q=0-4;

r = 1-4;

s = 1-6;

u = 0-4 and v = 0-4 , wherein the sum of u+v is 2-4;

20 or a pharmaceutically acceptable salt thereof,

provided that

when R₆ is alkenyl of 2-7 carbon atoms or alkynyl of 2-7 carbon atoms, such alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;

25 and further provided that

when Y is -NR₆- and R₇ is -NR₆R₆, -N(R₆)₃ , or -NR₆(OR₆), then g = 2-6;

when M is -O- and R₇ is -OR₆, then p = 1-4;

- 34 -

when Y is -NR₆⁻, then k = 2-4;

when Y is -O- and M or W is -O-, then k = 1-4

when W is not a bond with Het bonded through a nitrogen atom, then q = 2-4

and when W is a bond with Het bonded through a nitrogen atom and Y is -O- or
5 -NR₆⁻, then k = 2-4.

With respect to the cyanoquinolines of Formula 4, the pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: acetic, lactic, citric, tartaric, succinic, maleic, malonic, gluconic, hydrochloric, hydrobromic,
10 phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids.

The alkyl portion of the alkyl, alkoxy, alkanoyloxy, alkoxymethyl, alkanoyloxymethyl, alkylsulphiny, alkylsulphonyl, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-alkylaminoalkoxy, N,N-dialkylaminoalkoxy, alkylsulfonamido, carboalkoxy, carboalkyl, carboxyalkyl, carboalkoxyalkyl, alkanoyl-amino, N-alkylcarbamoyl, and N,N-dialkylcarbamoyl substituents include both straight chain as well as branched carbon chains. The alkenyl portion of the alkenyl, alkenoyloxymethyl, alkenyloxy, alkenylsulfonamido, substituents include both straight chain as well as branched carbon chains and one or more sites of unsaturation and all possible configurational isomers. The alkynyl portion of the alkynyl, 15 alkynoyloxymethyl, alkynylsulfonamido, alkynyoxy, substituents include both straight chain as well as branched carbon chains and one or more sites of unsaturation. Carboxy is defined as a -CO₂H radical. Carboalkoxy of 2-7 carbon atoms is defined as a -CO₂R" radical, where R" is an alkyl radical of 1-6 carbon atoms. Carboxyalkyl is defined as a HO₂C-R"" radical where R"" is a divalent alkyl radical of 1-6 carbon atoms. Carboalkoxyalkyl is defined as a R"O₂C-R"" radical where R"" is a divalent 20 alkyl radical and where R" and R"" together have 2-7 carbon atoms. Carboalkyl is defined as a -COR" radical, where R" is an alkyl radical of 1-6 carbon atoms. Alkanoyloxy is defined as a -OCOR" radical, where R" is an alkyl radical of 1-6 carbon atoms. Alkanoyloxymethyl is defined as R"CO₂CH₂- radical, where R" is an 25 alkyl radical of 1-6 carbon atoms. Alkoxymethyl is defined as R"OCH₂- radical, where R" is an alkyl radical of 1-6 carbon atoms. Alkylsulphiny is defined as R"SO- radical, where R" is an alkyl radical of 1-6 carbon atoms. Alkylsulphonyl is defined as

- 35 -

R"SO₂- radical, where R" is an alkyl radical of 1-6 carbon atoms. Alkylsulfonamido, alkenylsulfonamido, alkynylsulfonamido are defined as R"SO₂NH- radical, where R" is an alkyl radical of 1-6 carbon atoms, an alkenyl radical of 2-6 carbon atoms, or an alkynyl radical of 2-6 carbon atoms, respectively. N-alkylcarbamoyl is defined as
5 R"NHCO- radical, where R" is an alkyl radical of 1-6 carbon atoms. N,N-dialkylcarbamoyl is defined as R"R'NCO- radical, where R" is an alkyl radical of 1-6 carbon atoms, R' is an alkyl radical of 1-6 carbon atoms and R', and R" may be the same or different. When X is substituted, it is preferred that it is mono-, di-, or tri-
10 substituted, with monosubstituted being most preferred. It is preferred that of the substituents R1 and R4, at least one is hydrogen and it is most preferred that both be hydrogen. It is also preferred that X is a phenyl ring, Z is -NH-, and n = 0.

Het is a heterocycle, as defined above which may be optionally mono- or di-substituted with R₆ on carbon or nitrogen, optionally mono- or di-substituted on carbon with hydroxy, -N(R₆)₂, or -OR₆, optionally mono or di-substituted on carbon
15 with -(C(R₆)₂)_sOR₆ or -(C(R₆)₂)_sN(R₆)₂, and optionally mono or di-substituted on a saturated carbon with divalent radicals -O- or -O(C(R₆)₂)_sO-(carbonyl and ketal groups, respectively); in some cases when Het is substituted with -O- (carbonyl), the carbonyl group can be hydrated. Het may be bonded to W when q = 0 via a carbon atom on the heterocyclic ring, or when Het is a nitrogen containing
20 heterocycle which also contains a saturated carbon-nitrogen bond, such heterocycle may be bonded to carbon, via the nitrogen when W is a bond. When q = 0 and Het is a nitrogen containing heterocycle which also contains an unsaturated carbon-nitrogen bond, that nitrogen atom of the heterocycle may be bonded to carbon when W is a bond and the resulting heterocycle will bear a positive charge. When Het is
25 substituted with R₆, such substitution may be on a ring carbon, or in the case of a nitrogen containing heterocycle, which also contains a saturated carbon-nitrogen, such nitrogen may be substituted with R₆ or in the case of a nitrogen containing heterocycle, which also contains an unsaturated carbon-nitrogen, such nitrogen may be substituted with R₆ in with case the heterocycle will bear a positive charge.
30 Preferred heterocycles include pyridine, 2,6-disubstituted morpholine, 2,5-disubstituted thiomorpholine, 2-substituted imidazole, substituted thiazole,

- 36 -


thiazolidine, N-substituted imidazole, N-substituted 1,4-piperazine, N-substituted piperadine, dioxane, 1,3-dioxolane, and N-substituted pyrrolidine.

The compounds Formula 4 may contain one or more asymmetric carbons atoms; in such cases, the compounds of Formula 4 include the individual 5 diasteromers, the racemates, and the individual R and S enantiomers thereof. Some of the compound of Formula 4 may contain one or more double bonds; in such cases, the compounds of Formula 4 include each of the possible configurational isomers as well as mixtures of these isomers.

10

E. Naphthyridines of Formula 5, which are disclosed in US Patent Application SN 09/295,507. These compounds can be prepared according to the methodology described in US Patent Application SN 09/295,507, which is hereby incorporated by reference. The structure of the EGFR kinase inhibitors of Formula 5 are as follows:

15



5

wherein:

- 20 X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or
 X is pyridinyl, pyrimidinyl, or Ph; or
 X is a bicyclic aryl or bicyclic heteroaryl ring system of 8 to 12 atoms, where the bicyclic heteroaryl ring contains 1 to 4 heteroatoms selected from N, O, and S;
 25 wherein the bicyclic aryl or bicyclic heteroaryl ring may be optionally mono-, di-, tri-, or tetra-substituted with a substituent selected from the group consisting of halogen, oxo, thio, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxyethyl of 2-7 carbon atoms, alkanoyloxyethyl of

- 37 -

2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 5 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 10 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino; or

X is the radical $\begin{array}{c} / \text{E} \\ \text{T} \\ \backslash \end{array} \text{L}$;

E is pyridinyl, pyrimidinyl, or Ph;

T is substituted on E at carbon and is

15 - NH(CH₂)_m-, -O(CH₂)_m-, -S(CH₂)_m-, -NR(CH₂)_m-, -(CH₂)_m-
-(CH₂)_mNH-, - (CH₂)_mO-, - (CH₂)_mS-, or - (CH₂)_mNR-;

L is a Ph; or

15 L is a 5- or 6-membered heteroaryl ring where the heteroaryl ring contains 1 to 3 heteroatoms selected from N, O, and S; wherein the heteroaryl ring may be 20 optionally mono- or di-substituted with a substituent selected from the group consisting of halogen, oxo, thio, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxyymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 25 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 30 3-10 carbon atoms;

- 38 -


2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino;

Pyridinyl, pyrimidinyl, or Ph are pyridinyl, pyrimidinyl, or phenyl radicals, respectively, which may be optionally mono-, di-, or tri-substituted with a
 5 substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxyethyl of 2-7 carbon atoms, alkanoyloxyethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy,
 10 carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, benzoyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-
 15 alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino;

Z is -NH-, -O-, -S-, or -NR- ;

R is alkyl of 1-6 carbon atoms, or carboalkyl of 2-7 carbon atoms;

20 A" is a diivalent moiety selected from the group




G1, G2, G3, and G4 are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyoxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 2-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxyethyl of 2-7 carbon atoms, alkenoyloxyethyl of 4-9 carbon atoms, alkynoyloxyethyl of 4-9 carbon atoms, alkoxyethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms,

25 alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyoxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 2-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxyethyl of 2-7 carbon atoms, alkenoyloxyethyl of 4-9 carbon atoms, alkynoyloxyethyl of 4-9 carbon atoms, alkoxyethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms,

- 39 -


alkylthio of 1-6 carbon atoms, alkylsulphanyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, trifluoromethoxy, cyano, nitro, carboxy, 5 carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-N-alkenylamino of 10 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino, R₂NH,



15 R₇-(C(R₆)₂)_g-Y-, R₇-(C(R₆)₂)_p-M-(C(R₆)₂)_k-Y-, Het-(C(R₆)₂)_q-W-(C(R₆)₂)_k-Y-,

with the proviso that G₃ and G₄ are not R₂NH;

Y is a divalent radical selected from the group consisting of



R₇ is -NR₆R₆, -OR₆, -J, -N(R₆)₃, or -NR₆(OR₆);

20 M is >NR₆, -O-, >N-(C(R₆)₂)_pNR₆R₆, or >N-(C(R₆)₂)_p-OR₆;


W is >NR₆, -O- or is a bond;

Het is a heterocyclic radical selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine, aziridine, pyridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, thiazole, thiazolidine, tetrazole, piperazine, furan, thiophene,

25

- 40 -

tetrahydrothiophene, tetrahydrofuran, dioxane, 1,3-dioxolane, tetrahydro-



pyran, and which may be optionally mono- or di-substituted on carbon with R₆, hydroxy,


-N(R₆)₂, -OR₆ -(C(R₆)₂)_sOR₆ or -(C(R₆)₂)_sN(R₆)₂;

- 5 optionally mono-substituted on nitrogen with R₆; and
 optionally mono or di-substituted on a saturated carbon with divalent radicals
 -O- or -O(C(R₆)₂)_sO-;


R₆ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl 2-7 carbon atoms, phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido, halomethyl, alkoxyethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms; with the proviso that the alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;

- 10 15 20 R₂, is selected from the group consisting of


- 41 -




- 42 -




R₃ is hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms,
phenyl, carboalkyl of 2-7 carbon atoms,



R₅ is hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms,
10 phenyl, carboalkyl of 2-7 carbon atoms,



- 43 -



R₈, and R₉ are each, independently, -(C(R₆)₂)_rNR₆R₆, or -(C(R₆)₂)_rOR₆;

J is independently hydrogen, chlorine, fluorine, or bromine;

5 Q is alkyl of 1-6 carbon atoms or hydrogen;

a = 0-1;

g = 1-6;

k = 0-4;

n is 0-1;

10 m is 0-3;

p = 2-4;

q = 0-4;

r = 1-4;

s = 1-6;

15 u = 0-4 and v = 0-4, wherein the sum of u+v is 2-4;

or a pharmaceutically acceptable salt thereof,

provided that

when R₆ is alkenyl of 2-7 carbon atoms or alkynyl of 2-7 carbon atoms, such

alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom

20 through a saturated carbon atom;

and provided that

when R₃ is bound to sulfur, it cannot be hydrogen, carboxy, carboalkoxy, or

carboalkyl;

and provided that

25 when Y is -NR₆- and R₇ is -NR₆R₆, -N(R₆)₃, or -NR₆(OR₆), then g = 2-6;

when M is -O- and R₇ is -OR₆ then p = 1-4;

when Y is -NR₆- then k = 2-4;

when Y is -O- and M or W is -O- then k = 1-4


when W is not a bond with Het bonded through a nitrogen atom then q = 2-4

- 44 -

and when W is a bond with Het bonded through a nitrogen atom and Y is -O- or -NR₆- then k = 2-4;

and finally provided that

when A" is the moiety



5

n = 0,

Z is NH,

G₁ is hydrogen, halogen, alkyl, alkoxy, hydroxy, alkanoyloxy of 2-6 carbon atoms, or phenoxy, and

10 G₂ is hydrogen, halogen, alkyl, hydroxy, carboxyalkyl, carboalkoxyalkyl, hydroxyalkyl, alkoxy, halomethyl, carboxyl, carboalkoxy, alkanoylamino, or alkenoylamino,

then X can not be a pyridinyl, pyrimidinyl, or phenyl ring that is substituted with a hydroxy or alkoxy group.

15

With respect to the naphthyridines of Formula 5, The pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: acetic, lactic, citric, tartaric, succinic, maleic, malonic, gluconic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids.

20

Preferred bicyclic aryl or bicyclic heteroaryl ring systems include naphthalene, 1,2,3,4-tetrahydronaphthalene, tetralin, indane, 1-oxo-indane, 1,2,3,4-tetrahydroquinoline, naphthyridine, benzofuran, 3-oxo-1,3-dihydro-isobenzofuran, benzothiophene, 1,1-dioxo-benzothiophene, indole, 2,3-dihydroindole, 1,3-dioxo-2,3-dihydro-1H-isoindole, benzotriazole, 1H-indazole, indoline, benzopyrazole, 1,3-benzodioxole, benzooxazole, purine, phthalimide, coumarin, chromone, quinoline, terahydroquinoline, isoquinoline, benzimidazole, quinazoline, pyrido[2,3-b]pyridine, pyrido[3,4-b]pyrazine, pyrido[3,2-c]pyridazine, pyrido[3,4-b]pyridine, 1H-pyrazole-[3,4-d]pyrimidine, 1,4-benzodioxane, pteridine, 2(1H)-quinolone, 1(2H)-iso-

- 45 -

quinolone, 2-oxo-2,3-dihydro-benzthiazole, 1,2-methylenedioxybenzene, 2-oxindole, 1,4-benzisoxazine, benzothiazole, quinoxaline, quinoline-N-oxide, isoquinoline-N-oxide, quinoxaline-N-oxide, quinazoline-N-oxide, benzoazine, phthalazine, 1,4-dioxo-1,2,3,4-tetrahydro-phthalazine, 2-oxo-1,2-dihydro-quinoline, 2,4-dioxo-
5 1,4-dihydro-2H-benzo[d][1,3]oxazine, 2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[e]-[1,4]diazepine, or cinnoline.

When L is a 5 or 6-membered heteroaryl ring, preferred heteroaryl rings include pyridine, pyrimidine, imidazole, thiazole, thiazolidine, pyrrole, furan, 10 thiophene, oxazole, or 1,2,4-triazole.

Either or both rings of the bicyclic aryl or bicyclic heteroaryl group may be fully unsaturated, partially saturated, or fully saturated. An oxo substituent on the bicyclic aryl or bicyclic heteroaryl moiety means that one of the carbon atoms has a carbonyl group. A thio substituent on the bicyclic aryl or bicyclic heteroaryl moiety means that one of the carbon atoms has a thiocarbonyl group. When a compound of 15 Formula 5 contains a moiety which contains a heteroaryl ring, such heteroaryl ring does not contain O-O, S-S, or S-O bonds in the ring.

20 When L is a 5 or 6-membered heteroaryl ring, it may be fully unsaturated, partially saturated, or fully saturated. The heteroaryl ring can be bound to T via carbon or nitrogen. An oxo substituent on the heteroaryl ring means that one of the carbon atoms has a carbonyl group. A thio substituent on the heteroaryl ring means that one of the carbon atoms has a thiocarbonyl group.

25

The alkyl portion of the alkyl, alkoxy, alkanoyloxy, alkoxymethyl, alkanoyloxyethyl, alkylsulphanyl, alkylsulphonyl, alkylsulfonamido, carboalkoxy, carboalkyl, carboxyalkyl, carboalkoxyalkyl, alkanoylamino, N-alkylcarbamoyl, and N,N-dialkylcarbamoyl, N-alkylaminoalkoxy, N,N-dialkylaminoalkoxy include both 30 straight chain as well as branched carbon chains. The alkenyl portion of the alkenyl, alkenoyloxyethyl, alkenyloxy, alkenylsulfonamido, substituents include both straight chain as well as branched carbon chains and one or more sites of unsaturation and all possible configurational isomers. The alkynyl portion of the alkynyl,

- 46 -

alkynoyloxyethyl, alkynylsulfonamido, alkynyoxy, substituents include both straight chain as well as branched carbon chains and one or more sites of unsaturation. Carboxy is defined as a $\text{-CO}_2\text{H}$ radical. Carboalkoxy of 2-7 carbon atoms is defined as a $\text{-CO}_2\text{R}''$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Carboxyalkyl 5 is defined as a $\text{HO}_2\text{C-R}'''$ - radical where R''' is a divalent alkyl radical of 1-6 carbon atoms. Carboalkoxyalkyl is defined as a $\text{R''O}_2\text{C-R}'''$ - radical where R''' is a divalent alkyl radical and where R'' and R''' together have 2-7 carbon atoms. Carboalkyl is defined as a $\text{-COR}''$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkanoyloxy is defined as a $\text{-OCOR}''$ radical, where R'' is an alkyl radical of 1-6 10 carbon atoms. Alkanoyloxyethyl is defined as $\text{R''CO}_2\text{CH}_2\text{-}$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkoxyethyl is defined as $\text{R''OCH}_2\text{-}$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkylsulphinyl is defined as $\text{R''SO}_2\text{-}$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. Alkylsulphonyl is defined as $\text{R''SO}_2\text{-}$ radical, where R'' is an alkyl radical of 1-6 carbon atoms. 15 Alkylsulfonamido, alkenylsulfonamido, alkynylsulfonamido are defined as $\text{R''SO}_2\text{NH-}$ radical, where R'' is an alkyl radical of 1-6 carbon atoms, an alkenyl radical of 2-6 carbon atoms, or an alkynyl radical of 2-6 carbon atoms, respectively. N-alkylcarbamoyl is defined as R''NHCO- radical, where R'' is an alkyl radical of 1-6 carbon atoms. N,N-dialkylcarbamoyl is defined as $\text{R''R'}\text{NCO-}$ radical, where R'' is 20 an alkyl radical of 1-6 carbon atoms, R' is an alkyl radical of 1-6 carbon atoms and R' , and R'' may be the same or different. When X is substituted, it is preferred that it is mono-, di-, or tri-substituted, with mono- and di-substituted being most preferred. It is preferred that of the substituents G_1 and G_4 , at least one is hydrogen and it is most preferred that both be hydrogen. It is also preferred that X is a phenyl ring, Z is -NH- , 25 and $\text{n} = 0$.

Het is a heterocycle, as defined above which may be optionally mono- or di-substituted on carbon with R_6 , optionally mono-substituted on nitrogen with R_6 , optionally mono- or di-substituted on carbon with hydroxy, $\text{-N(R}_6\text{)}_2$, or -OR_6 , 30 optionally mono or di-substituted on carbon with $\text{-(C(R}_6\text{)}_2\text{)}_s\text{OR}_6$ or $\text{-(C(R}_6\text{)}_2\text{)}_s\text{N(R}_6\text{)}_2$, and optionally mono or di-substituted on a saturated carbon with

- 47 -

divalent -O- or -O(C(R₆)₂)₂O- (carbonyl and ketal groups , respectively); in some cases when Het is substituted with -O- (carbonyl), the carbonyl group can be hydrated. Het may be bonded to W when q = 0 via a carbon atom on the heterocyclic ring, or when Het is a nitrogen containing heterocycle which also contains a saturated

5 carbon-nitrogen bond, such heterocycle may be bonded to carbon, via the nitrogen when W is a bond. When q = 0 and Het is a nitrogen containing heterocycle which also contains an unsaturated carbon-nitrogen bond, that nitrogen atom of the heterocycle may be bonded to carbon when W is a bond and the resulting heterocycle will bear a positive charge. When Het is substituted with R₆, such substitution may

10 be on a ring carbon, or in the case of a nitrogen containing heterocycle, which also contains a saturated carbon-nitrogen, such nitrogen may be substituted with R₆ or in the case of a nitrogen containing heterocycle, which also contains an unsaturated carbon-nitrogen, such nitrogen may be substituted with R₆ in with case the heterocycle will bear a positive charge. Preferred heterocycles include pyridine, 2,6-

15 disubstituted morpholine, 2,5-disubstituted thiomorpholine, 2-substituted imidazole, substituted thiazole, N-substituted imidazole, N-substituted 1,4-piperazine, N- substituted piperadine, and N-substituted pyrrolidine.

The compounds of Formula 5 may contain one or more asymmetric carbon atoms; in such cases, the compounds of Formula 5 include the individual

20 diasteromers, the racemates, and the individual R and S enantiomers thereof. Some of the compound of Formula 5 may contain one or more double bonds; in such cases, the compounds of Formula 5 include each of the possible configurational isomers as well as mixtures of these isomers. When a compound of Formula 5 contains a moiety containing the same substituent more than once (for example, when R₁ is -NR₆R₆),

25 each substituent (R₆ in this example) may be the same or different.

F. Phenylamino quinazolines disclosed in WO 97/38983; 4-anilino quinolines disclosed in WO 96/09294 and WO 98/13350; quinolines disclosed in US Patent

30 5,480,833, WO 98/02434, and WO 98/02438; quinazolines disclosed in EP 520722, EP 566226, WO96/09294, WO 95/24190, WO 95/21613, WO 95/15758, EP 602851, EP 635498, WO 95/19774, WO 95/19970, EP 635507, WO 95/157581, WO 95/23141, WO 96/33977, WO 96/33978, WO 96/33979, WO 96/33980,

- 48 -

WO 96/33981; tricyclic EGFR inhibitors disclosed in WO 95/19970; pyrrolopyrimidines disclosed in EP 682027; benzylidine-1,3-dihydro-indol-2-ones disclosed in WO 99/10325; tricyclic quinoxalines disclosed in WO 99/07701; pyrrolo[2,3d]pyrimidines disclosed in WO 98/41525; 2-pyrimidineamines disclosed 5 in WO 98/18782 and WO 98/11095; 2-anilinopyrimidines disclosed in WO 97/19065; heterocyclic ring fused pyrimidines disclosed in WO 96/40142; benzylidine and cinnamylidine-malononitriles disclosed in EP 614661; 4-heterocycl-substituted quinazolines disclosed in US Patent 5,736,534; (4-substituted phenylamino)quinazolines disclosed in US Patent 5,747,498;

10

The ability of a combination of an NSAID and EGFR kinase inhibitor to treat or inhibit colonic polyps was demonstrated in an *in vivo* standard pharmacological test procedure as described below, using sulindac as a representative NSAID and 15 N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (a member of the EGFR kinase inhibitors of Formula 1) and (4-dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide (a member of the EGFR kinase inhibitors of Formula 2) as a representative EGFR kinase inhibitors. The preparation and activity of N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2- 20 butynamide as an EGFR kinase inhibitor are described in US Patent 5,760,041. The preparation and activity of (4-dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide as an EGFR kinase inhibitor are described in US Patent 6,002,008.

The procedure described below emulates familial adenomatous polyposis (FAP) 25 in humans using the Min mouse (C57BL/6J-Min+), which is a strain which has lost both copies of the APC gene. These animals develop multiple intestinal polyps (adenomas) that ultimately progress to form adenocarcinomas. The polyps that develop in Min mice express EGFR and have activated COX-2. NSAID's such as sulindac and etodolac can reduce (but not eradicate) intestinal polyp formulation in 30 these animals indicating that COX-2 and the ultimate production of PG's is likely responsible for these effects. The following briefly describes the procedure used and the results obtained in this standard pharmacological test procedure.

- 49 -

Test animals were divided into four treatment groups: Group I, control; Group II, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide; Group III, sulindac; and Group IV, combination of sulindac and N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (hereinafter referred to as the NSAID/EGFR kinase inhibitor combination). The test compound was blended with a standard murine chow and animals were given ad libitum access to the food, in quantities corresponding to the following approximate daily dosages: Group II - 40 mg/kg/day N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide; Group III - 20 mg/kg/day sulindac; and Group IV - 40 mg/kg/day N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide and 20 mg/kg/day sulindac. The animals were treated for 60 days. The food was weighed once per week to determine consumption, and the animals also weighed weekly. On day 61, the animals were euthanized with CO₂ inhalation, and the entire intestinal tract from stomach to anus was removed. The intestinal tract was injected with Bouins fixative, and allowed to fix for several days. The intestinal tracts were then opened and the number of polyps counted. Statistical analysis was performed using the Student's t-Test; a p value of ≤ 0.05 is considered statistically significant.

The following table summarizes the results that were obtained with N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide.

Treatment Group	Number of Polyps	P value
Group I	32.3 ± 20.7	
Group II	15.6 ± 10.6	< 0.001
Group III	10.0 ± 6.6	< 0.001
Group IV	1.0 ± 0.96	< 0.001

20

The results obtained in this standard pharmacological test procedure showed that treatment with either sulindac or N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide alone reduced polyp numbers between 50 and 68 percent. The NSAID/EGFR kinase inhibitor combination reduced polyp numbers to virtually zero, clearly showing a synergistic interaction between the NSAID and the EGFR kinase inhibitor.

- 50 -

The above standard pharmacological test procedure was run again using lower dosages of sulindac in combination with an EGFR kinase inhibitor, as follows: Group I - control; Group II - 40 mg/kg/day N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide and 10 mg/kg/day sulindac; and Group III - 5 mg/kg/day N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide and 20 mg/kg/day sulindac. The following results were obtained.

Treatment Group	Number of Polyps	P value
Group I	37.0 ± 27.9	
Group II	0.83 ± 1.33	< 0.001
Group III	0.07 ± 0.26	< 0.001

The above standard pharmacological test procedure was run again using
10 (4-dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide as a representative EGFR kinase inhibitor, as follows. Test animals were divided into four treatment groups: Group I, control; Group II, (4-dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide Group III, sulindac; and Group IV, combination of
15 sulindac and (4-dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide. The test compound was blended with a standard murine chow and animals were given ad libitum access to the food, in quantities corresponding to the following approximate daily dosages: Group II - 20 mg/kg/(4-dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide ; Group III - 5 mg/kg/day sulindac; and Group IV - 20 mg/kg/(4-dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide and 5 mg/kg/day sulindac. The animals were treated for 60 days. The food was weighed once per week to determine consumption, and the animals also weighed weekly. On day 61, the animals were
25 euthanized with CO₂ inhalation, and the entire intestinal tract from stomach to anus was removed. The intestinal tract was injected with Bouins fixative, and allowed to fix for several days. The intestinal tracts were then opened and the number of polyps

- 51 -

counted. Statistical analysis was performed using the Student's t-Test; a p value of ≤ 0.05 is considered statistically significant.

The following table summarizes the results that were obtained.

Treatment Group	Number of Polyps	P value
Group I	19.5 ± 14.1	
Group II	2.6 ± 1.6	< 0.001
Group III	20.6 ± 11.8	< 0.0001
Group IV	0.87 ± 1.1	< 0.001

5

The results obtained in this standard pharmacological test procedure showed that treatment with (4-dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide alone reduced polyp numbers 87 percent while sulindac alone at the 5mg/kg dose did not reduce polyp numbers at all.

10 The sulindac plus [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide combination reduced polyp numbers to virtually zero, again showing a synergistic interaction between the NSAID and an EGFR kinase inhibitor.

15 The results obtained in this standard pharmacological test procedure showed that the the NSAID/EGFR kinase inhibitor combination reduced the polyp numbers to virtually zero, at even lower doses of sulindac. Based on the results obtained in the standard pharmacological test procedure described above, the combinations of an NSAID with an EGFR kinase inhibitor is useful in treating or inhibiting colonic polyps and is also useful in treating or inhibiting colorectal cancer. It is also 20 anticipated that the use of the combination of an NSAID with an EGFR kinase inhibitor will significantly reduce the dosage of NSAID used to treat or inhibit colonic polyps or colorectal cancer, and thereby reduce the therapeutic liabilities associated with NSAID treatment.

25 The NSAID/EGFR kinase inhibitor combination of this invention may formulated neat or may be combined with one or more pharmaceutically acceptable carriers for administration. For example, solvents, diluents and the like, and may be

- 52 -

administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of
5 sterile injectable solution or suspension containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 0.05 up to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.

The effective dosage of each active ingredient employed may vary depending
10 on the particular compound employed, the mode of administration and the severity of the condition being treated. The projected daily dosage of the EGFR kinase inhibitor will depend on its potency. For the purpose of comparison N-[4-[(3-bromo-phenyl)amino]-6-quinazolinyl]-2-butynamide has an IC₅₀ of 2 nM in the test procedure which measured the inhibition of the phosphorylation of the tyrosine
15 residue of a peptide substrate catalyzed by EGFR kinase. Similarly, the projected dosage of the NSAID used depends on the relative potency of the NSAID, compared for example to sulindac. Numerous methods for evaluating and comparing NSAID potency are known in the literature. Based on the results obtained in the standard pharmacological test procedure utilizing the Min mouse, the projected oral daily dosage
20 of the NSAID would be in the range of 2 - 30 mg/kg, and the projected daily dosage of the EGFR kinase inhibitor would be in the range of 1 - 50 mg/kg. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. The NSAID and
25 the EGFR kinase inhibitor may also be administered as a combined dosage unit, or as separate components. When administered as separate components, each component may be administered at the same time, or at different times during the treatment period.

The NSAID/EGFR kinase inhibitor combination may be administered orally
30 as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired.
35 Adjuvants customarily employed in the preparation of pharmaceutical compositions

- 53 -

may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.

The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the NSAID/EGFR kinase inhibitor combination is preferred.

In some cases it may be desirable to administer the NSAID/EGFR kinase inhibitor combination directly to the airways in the form of an aerosol.

These NSAID/EGFR kinase inhibitor combination may also be administered 10 parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparation contain a preservative to 15 prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the 20 conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

- 54 -


CLAIMS

1. A method of treating or inhibiting colonic polyps in a mammal in need thereof which comprises administering to said mammal an effective amount of an NSAID and an EGFR kinase inhibitor.

2. The method according to claim 1, wherein the NSAID is selected from the group consisting of ibuprofen, sulindac, ketoporfén, fenoprofen, flurbiprofen, naproxen, tiaprofénic acid, suprofen, etodolac, carprofén, ketrolac, piprofen, indoprofen, celecoxib, rofecoxib, mobicox, and benoxaprofen.

3. The method according to claim 1, wherein the EGFR kinase inhibitor irreversibly inhibits EGFR kinase.

- 15 4. The method according to Claim 1, wherein the EGFR kinase inhibitor is a compound of formula 1, having the structure



20 wherein:

X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxyalkyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy,

- 55 -

- benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminomethyl, N-alkylaminomethyl of 2-7 carbon atoms, N,N-dialkylaminomethyl of 3-7 carbon atoms, mercapto, methylmercapto, and benzoylamino;
- Z is -NH-, -O-, -S-, or -NR- ;
- R is alkyl of 1-6 carbon atoms, or carboalkyl of 2-7 carbon atoms;
- 10 R₁, R₃, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyoxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino,

$R_7-(C(R_6)_2)_g-Y-$, $R_7-(C(R_6)_2)_p-M-(C(R_6)_2)_k-Y-$, or Het-W-(C(R₆)₂)_k-Y-

- 30 Y is a divalent radical selected from the group consisting of

$-(CH_2)_a-$, $-O-$, and $-N-$;


- R_7 is $-NR_6R_6$, or $-OR_6$;
- 35 M is $>NR_6$, $-O-$, $>N-(C(R_6)_2)_pNR_6R_6$, or $>N-(C(R_6)_2)_p-OR_6$;
- W is $>NR_6$, $-O-$ or is a bond;

- 56 -


Het is a heterocycle, optionally mono- or di-substituted on carbon or nitrogen with R₆ and optionally mono-substituted on carbon with -CH₂OR₆; wherein the heterocycle is selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine, aziridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, piperazine, tetrahydrofuran, and tetrahydropyran;

R₆ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl (2-7 carbon atoms), phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms;

R₂, is selected from the group consisting of





- 57 -



5

R_5 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,

- 58 -



R_8 , and R_9 are each, independently, $-(C(R_6)_2)_rNR_6R_6$, or $-(C(R_6)_2)_rOR_6$;

5

J is independently hydrogen, chlorine, fluorine, or bromine;

Q is alkyl of 1-6 carbon atoms or hydrogen;

$a = 0$ or 1 ;

$g = 1-6$;

10 $k = 0-4$;

$n = 0-1$;

$p = 2-4$;

$q = 0-4$;

$r = 1-4$;

15 $s = 1-6$;

$u = 0-4$ and $v = 0-4$, wherein the sum of $u+v$ is $2-4$;


or a pharmaceutically acceptable salt thereof.

5. The method according to Claim 4, wherein the EGFR kinase inhibitor
20 is N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide or a pharmaceutically
acceptable salt thereof.

6. The method according to Claim 5, wherein the NSAID is sulindac.

25 7. The method according to Claim 1, wherein the EGFR kinase inhibitor
is a compound of formula 2, having the structure

- 59 -









wherein:

- X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxyethyl of 2-7 carbon atoms, alkanoyloxyethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino;
- 5 n is 0-1;
- Y is -NH-, -O-, -S-, or -NR-;
- 10 R is alkyl of 1-6 carbon atoms;
- 15 R₁, R₂, R₃, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyoxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxyethyl of 2-7 carbon atoms, alkenoyloxyethyl of 4-9 carbon atoms, alkynoyloxyethyl of 4-9 carbon atoms, alkoxyethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms,
- 20
- 25

- 60 -

5 alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, aminoalkyl of 1-4 carbon atoms, N-alkylaminoalkyl of 2-7 carbon atoms, N,N-dialkylaminoalkyl of 3-14 carbon atoms, phenylamino, benzylamino,



- 61 -

R₅ is alkyl of 1-6 carbon atoms, alkyl optionally substituted with one or more halogen atoms, phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, nitro, cyano, or alkyl of 1-6 carbon atoms groups;

5 R₆ is hydrogen, alkyl of 1-6 carbon atoms, or alkenyl of 2-6 carbon atoms;

R₇ is chloro or bromo

R₈ is hydrogen, alkyl of 1-6 carbon atoms, aminoalkyl of 1-6 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-12 carbon atoms, N-cycloalkylaminoalkyl of 4-12 carbon atoms, N-cycloalkyl-N-

10 alkylaminoalkyl of 5-18 carbon atoms, N,N-dicycloalkylaminoalkyl of 7-18 carbon atoms, morpholino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, piperidino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, N-alkyl-piperidino-N-alkyl wherein either alkyl group is 1-6 carbon atoms, azacycloalkyl-N-alkyl of 3-11 carbon atoms, hydroxyalkyl of 1-6 carbon

15 atoms, alkoxyalkyl of 2-8 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms, chloro, fluoro, or bromo;

Z is amino, hydroxy, alkoxy of 1-6 carbon atoms, alkylamino wherein the alkyl moiety is of 1-6 carbon atoms, dialkylamino wherein each of the alkyl moieties is of 1-6 carbon atoms, morpholino, piperazino, N-alkylpiperazino

20 wherein the alkyl moiety is of 1-6 carbon atoms, or pyrrolidino;

m = 1-4, q = 1-3, and p = 0-3;

any of the substituents R₁, R₂, R₃, or R₄ that are located on contiguous carbon atoms can together be the divalent radical -O-C(R₈)₂-O-;


or a pharmaceutically acceptable salt thereof with the proviso that when Y is -NH-, R₁, R₂, R₃, and R₄ are hydrogen, and n is 0, X is not 2-methylphenyl.

30 8. The method according to Claim 7, wherein the EGFR kinase inhibitor is (4-dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt therof.

9. The method according to Claim 8, wherein the NSAID is sulindac.

35 10. The method according to Claim 1, wherein the EGFR kinase inhibitor is a compound of formula 3, having the structure

- 62 -



wherein:

X is a bicyclic aryl or bicyclic heteroaryl ring system of 8 to 12 atoms where the
 5 bicyclic heteroaryl ring contains 1 to 4 heteroatoms selected from N, O, and S
 with the proviso that the bicyclic heteroaryl ring does not contain O-O, S-S, or
 10 S-O bonds and where the bicyclic aryl or bicyclic heteroaryl ring may be
 optionally mono-, di-, tri, or tetra-substituted with a substituent selected from
 the group consisting of halogen, oxo, thio, alkyl of 1-6 carbon atoms, alkenyl
 15 of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6
 carbon atoms, halomethyl, alkoxyethyl of 2-7 carbon atoms, alkanoyloxyethyl of 2-7
 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy,
 trifluoromethyl, cyano, nitro, carboxy,
 20 carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy,
 phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon
 atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino,
 alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms,
 alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms,
 25 carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-
 alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon
 atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of
 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino; or

X is a radical radical having the formula:



25 wherein A is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl,
 pyrimidinyl, or phenyl ring may be optionally mono- or di-substituted with a
 substituent selected from the group consisting of halogen, alkyl of 1-6 carbon

- 63 -

atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, 5 carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, 10 carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino;

T is bonded to a carbon of A and is:

15 - NH(CH₂)_m- , -O(CH₂)_m- , -S(CH₂)_m- , -NR(CH₂)_m- , -(CH₂)_m-
 -(CH₂)_mNH- , - (CH₂)_mO- , - (CH₂)_mS- , or - (CH₂)_mNR- ;

L is an unsubstituted phenyl ring or a phenyl ring mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, 20 alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 25 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino; provided that L can be an unsubstituted phenyl ring only when m > 0 and T is not -CH₂NH- or -CH₂O-; or

- 64 -

L is a 5- or 6-membered heteroaryl ring where the heteroaryl ring contains 1 to 3 heteroatoms selected from N, O, and S, with the proviso that the heteroaryl ring does not contain O-O, S-S, or S-O bonds, and where the heteroaryl ring is optionally mono- or di-substituted with a substituent selected from the group consisting of halogen, oxo, thio, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino;


Z is -NH-, -O-, -S-, or -NR- ;

20 R is alkyl of 1-6 carbon atoms, or carboalkyl of 2-7 carbon atoms; G₁, G₂, R₁, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyoxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, trifluoromethoxy, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4

- 65 -

carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino,

5



$R_7-(C(R_6)_2)_q-Y-$, $R_7-(C(R_6)_2)_p-M-(C(R_6)_2)_k-Y-$, or Het- $(C(R_6)_2)_q-W-(C(R_6)_2)_k-Y-$;

10 or R_1 and R_4 are as defined above and G_1 or G_2 or both are

R_2-NH- ;

or if any of the substituents R_1 , G_2 , G_3 , or R_4 are located on contiguous carbon atoms then they may be taken together as the divalent radical $-O-C(R_6)_2-O-$;

15 Y is a divalent radical selected from the group consisting of

$-(CH_2)_a-$, $-O-$, and $-N_{R_6}-$;

R_7 is $-NR_6R_6$, $-OR_6$, $-J$, $-N(R_6)_3^+$, or $-NR_6(OR_6)$;

20


M is $>NR_6$, $-O-$, $>N-(C(R_6)_2)_pNR_6R_6$, or $>N-(C(R_6)_2)_p-OR_6$;

W is $>NR_6$, $-O-$ or is a bond;

Het is selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine,

25 aziridine, pyridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, thiazole, thiazolidine, tetrazole, piperazine, furan, thiophene, tetrahydrothiophene,

tetrahydrofuran, dioxane, 1,3-dioxolane, tetrahydropyran, and




- 66 -







wherein Het is optionally mono- or di-substituted on carbon or nitrogen with R₆, optionally mono- or di-substituted on carbon with hydroxy, -N(R₆)₂, or -OR₆, optionally mono or di-substituted on carbon with the mono-valent radicals -(C(R₆)₂)_sOR₆ or -(C(R₆)₂)_sN(R₆)₂, and optionally mono or di-substituted on a saturated carbon with divalent radicals -O- or -O(C(R₆)₂)_sO-;

R₆ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl (2-7 carbon atoms), phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms; with the proviso that the alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;

R₂, is selected from the group consisting of




- 67 -



5

R3 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,

- 68 -




$\text{R}_7\text{-(C(R}_6\text{)}_2\text{)}_s\text{-}$

$\text{R}_7\text{-(C(R}_6\text{)}_2\text{)}_p\text{-M-(C(R}_6\text{)}_2\text{)}_r\text{-}$

$\text{R}_8\text{R}_9\text{-CH-M-(C(R}_6\text{)}_2\text{)}_r\text{-}$, or $\text{Het-(C(R}_6\text{)}_2\text{)}_q\text{-W-(C(R}_6\text{)}_2\text{)}_r\text{-}$

5

R_5 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,



10

$\text{R}_7\text{-(C(R}_6\text{)}_2\text{)}_s\text{-}$

$\text{R}_7\text{-(C(R}_6\text{)}_2\text{)}_p\text{-M-(C(R}_6\text{)}_2\text{)}_r\text{-}$

$\text{R}_8\text{R}_9\text{-CH-M-(C(R}_6\text{)}_2\text{)}_r\text{-}$, or $\text{Het-(C(R}_6\text{)}_2\text{)}_q\text{-W-(C(R}_6\text{)}_2\text{)}_r\text{-}$

R_8 , and R_9 are each, independently, $-(\text{C(R}_6\text{)}_2)_r\text{NR}_6\text{R}_6$, or $-(\text{C(R}_6\text{)}_2)_r\text{OR}_6$;

J is independently hydrogen, chlorine, fluorine, or bromine;

Q is alkyl of 1-6 carbon atoms or hydrogen;

15 $\text{a} = 0$ or 1;

$\text{g} = 1\text{-}6$;

$\text{k} = 0\text{-}4$;

n is 0-1;

m is 0-3;

20 $\text{p} = 2\text{-}4$;

$\text{q} = 0\text{-}4$;

- 69 -

$r = 1\text{-}4;$

$s = 1\text{-}6;$

$u = 0\text{-}4$ and $v = 0\text{-}4$, wherein the sum of $u+v$ is 2-4;

or a pharmaceutically acceptable salt thereof,

5 provided that

when R_6 is alkenyl of 2-7 carbon atoms or alkynyl of 2-7 carbon atoms, such alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;

and further provided that

10 when Y is $-NR_6-$ and R_7 is $-NR_6R_6$, $-N(R_6)_3^+$, or $-NR_6(OR_6)$, then $g = 2\text{-}6$;

when M is $-O-$ and R_7 is $-OR_6$ then $p = 1\text{-}4$;

when Y is $-NR_6-$ then $k = 2\text{-}4$;


when Y is $-O-$ and M or W is $-O-$ then $k = 1\text{-}4$

when W is not a bond with Het bonded through a nitrogen atom then $q = 2\text{-}4$

15 and when W is a bond with Het bonded through a nitrogen atom and Y is $-O-$ or $-NR_6-$ then $k = 2\text{-}4$.

11. The method according to Claim 1, wherein the EGFR kinase inhibitor is a compound of formula 4, having the structure

20



wherein:

X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one


or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or

25 phenyl ring wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon

- 70 -


- atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, 5 benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 10 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino;
- Z is -NH-, -O-, -S-, or -NR- ;
- 15 R is alkyl of 1-6 carbon atoms, or carboalkyl of 2-7 carbon atoms; G1, G2, R₁, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyoxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, 20 alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, 25 hydroxy, trifluoromethyl, trifluoromethoxy, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-N-alkenylamino of 30 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino,

- 71 -



$\text{R}_7\text{-(C(R}_6\text{)}_2\text{)}_g\text{-Y-}$, $\text{R}_7\text{-(C(R}_6\text{)}_2\text{)}_p\text{-M-(C(R}_6\text{)}_2\text{)}_k\text{-Y-}$, or $\text{Het-(C(R}_6\text{)}_2\text{)}_q\text{-W-(C(R}_6\text{)}_2\text{)}_k\text{-Y-}$,


with the proviso that either G₁ or G₂ or both G₁ and G₂ must be a radical selected from the group



$\text{R}'_7\text{-(C(R}_6\text{)}_2\text{)}_g\text{-Y-}$, $\text{R}_7\text{-(C(R}_6\text{)}_2\text{)}_p\text{-M-(C(R}_6\text{)}_2\text{)}_k\text{-Y-}$, $\text{Het-(C(R}_6\text{)}_2\text{)}_q\text{-W-(C(R}_6\text{)}_2\text{)}_k\text{-Y-}$,

or $\text{R}_2\text{-N}^{\text{H}}\text{-}$;

5 Y is a divalent radical selected from the group consisting of



R₇ is $-\text{NR}_6\text{R}_6$, $-\text{J}$, $-\text{OR}_6$, $-\text{N}(\text{R}_6)_3^+$, or $-\text{NR}_6(\text{OR}_6)$;

R'₇ is $-\text{NR}_6(\text{OR}_6)$, $-\text{N}(\text{R}_6)_3^+$, alkenoxy of 1-6 carbon atoms, alkynoxy of 1-6 carbon atoms, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino

10 of 6-12 carbon atoms, N-alkyl-N-alkynylamino of 4 to 12 carbon atoms, N-alkenyl-N-alkynylamino of 4 to 12 carbon atoms, or N,N-dialkynylamino of 6-12 carbon atoms with the proviso that the alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;


M is $>\text{NR}_6$, $-\text{O-}$, $>\text{N-(C(R}_6\text{)}_2\text{)}_p\text{NR}_6\text{R}_6$, or $>\text{N-(C(R}_6\text{)}_2\text{)}_p\text{-OR}_6$;

15 W is $>\text{NR}_6$, $-\text{O-}$ or is a bond;

Het is a heterocycle selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine, aziridine, pyridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, thiazole, thiazolidine, tetrazole, piperazine, furan, thiophene,

- 72 -

tetrahydrothiophene, tetrahydrofuran, dioxane, 1,3-dioxolane, tetrahydro-




wherein the heterocycle is optionally mono- or di-substituted on carbon or nitrogen with R₆, optionally mono- or di-substituted on carbon with hydroxyl,

5 -N(R₆)₂, or -OR₆, optionally mono or di-substituted on carbon with the mono-valent radicals -(C(R₆)₂)_sOR₆ or -(C(R₆)₂)_sN(R₆)₂, or optionally mono or di-substituted on a saturated carbon with divalent radicals -O- or -O(C(R₆)₂)_sO-;








R₆ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-

10 6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl (2-7 carbon atoms), phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms;

R₂, is selected from the group consisting of




- 73 -



- 74 -

R3 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,




$$R_7-(C(R_6)_2)_S- \quad , \quad R_7-(C(R_6)_2)_P-M-(C(R_6)_2)_R-$$

R₈R₉-CH-M-(C(R₆)₂)_r, or Het-(C(R₆)₂)_q-W-(C(R₆)₂)_r;

5

with the proviso that at least one of the R₃ groups is selected from the group




$$R'_7-(C(R_6)_2)_s- \quad , \quad R_7.(C(R_6)_2)_p-M-(C(R_6)_2)_r-$$

$R_8R_9-CH-M-(C(R_6)_2)_r$, or $Het-(C(R_6)_2)_q-W-(C(R_6)_2)_r$;

10

R5 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,



$$R_7-(C(R_6)_2)_S- \quad , \quad R_7-(C(R_6)_2)_P-M-(C(R_6)_2)_R-$$

R₈R₉-CH-M-(C(R₆)₂)_r , or Het-(C(R₆)₂)_q-W-(C(R₆)₂)_r ;

15

R₈, and R₉ are each, independently, -(C(R₆)₂)_rNR₆R₆, or -(C(R₆)₂)_rOR₆;

- 75 -

J is independently hydrogen, chlorine, fluorine, or bromine;

Q is alkyl of 1-6 carbon atoms or hydrogen;

a = 0 or 1;

5 g = 1-6;

k = 0-4;

n is 0-1;

p = 2-4;

q=0-4;

10 r = 1-4;

s = 1-6;

u = 0-4 and v = 0-4 , wherein the sum of u+v is 2-4;

or a pharmaceutically acceptable salt thereof,

provided that

15 when R₆ is alkenyl of 2-7 carbon atoms or alkynyl of 2-7 carbon atoms, such alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;

and further provided that

when Y is -NR₆- and R₇ is -NR₆R₆, -N(R₆)₃⁺, or -NR₆(OR₆), then g = 2-6;

20 when M is -O- and R₇ is -OR₆, then p = 1-4;

when Y is -NR₆-, then k = 2-4;


when Y is -O- and M or W is -O-, then k = 1-4

when W is not a bond with Het bonded through a nitrogen atom, then q = 2-4

and when W is a bond with Het bonded through a nitrogen atom and Y is -O- or
25 -NR₆-, then k = 2-4 .

12. The method according to Claim 1, wherein the EGFR kinase inhibitor is a compound of formula 5, having the structure

- 76 -



5

wherein:

X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or

5 X is pyridinyl, pyrimidinyl, or Ph; or

X is a bicyclic aryl or bicyclic heteroaryl ring system of 8 to 12 atoms, where the bicyclic heteroaryl ring contains 1 to 4 heteroatoms selected from N, O, and S; wherein the bicyclic aryl or bicyclic heteroaryl ring may be optionally mono-, di-, tri-, or tetra-substituted with a substituent selected from the group consisting of halogen, oxo, thio, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxyethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino; or

X is the radical $\begin{array}{c} \diagup \\ E \\ \diagdown \end{array} \begin{array}{c} \diagdown \\ T \\ \diagup \end{array} L$;

25 E is pyridinyl, pyrimidinyl, or Ph;

T is substituted on E at carbon and is

- NH(CH₂)_m-, -O(CH₂)_m-, -S(CH₂)_m-, -NR(CH₂)_m-, -(CH₂)_m-

- 77 -

$-(CH_2)_mNH-$, $-(CH_2)_mO-$, $-(CH_2)_mS-$, or $-(CH_2)_mNR-$;

L is a Ph; or

- L is a 5- or 6-membered heteroaryl ring where the heteroaryl ring contains 1 to 3 heteroatoms selected from N, O, and S; wherein the heteroaryl ring may be 5 optionally mono- or di-substituted with a substituent selected from the group consisting of halogen, oxo, thio, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 10 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, 15 carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino;
- 20 Pyridinyl, pyrimidinyl, or Ph are pyridinyl, pyrimidinyl, or phenyl radicals, respectively, which may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, 25 carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, benzoyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, 30 N,N-dialkylaminoalkyl of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino;



- 78 -

atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino;

Z is -NH-, -O-, -S-, or -NR- ;

R is alkyl of 1-6 carbon atoms, or carboalkyl of 2-7 carbon atoms;

5 A" is a diivalent moiety selected from the group




G1, G2, G3, and G4 are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyoxy of 2-6 carbon atoms, hydroxymethyl,

10 halomethyl, alkanoyloxy of 2-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms; alkynoyloxymethyl of 4-9 carbon atoms; alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphanyl of 1-6 carbon atoms,


15 alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, trifluoromethoxy, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4

20 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino, R₂NH,

25




- 79 -



with the proviso that G3 and G4 are not R_2NH ;

- 5 Y is a divalent radical selected from the group consisting of



R_7 is $-NR_6R_6$, $-OR_6$, $-J$, $-N(R_6)_3^+$, or $-NR_6(OR_6)$;

M is $>NR_6$, $-O-$, $>N-(C(R_6)_2)_pNR_6R_6$, or $>N-(C(R_6)_2)_p-OR_6$;

W is $>NR_6$, $-O-$ or is a bond;

- 10 Het is a heterocyclic radical selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine, aziridine, pyridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, thiazole, thiazolidine, tetrazole, piperazine, furan, thiophene, tetrahydrothiophene, tetrahydrofuran, dioxane, 1,3-dioxolane, tetrahydro-


- 15 pyran, and
-
- which may be optionally mono- or di-substituted on carbon with R_6 , hydroxy, $-N(R_6)_2$, $-OR_6$, $-(C(R_6)_2)_sOR_6$ or $-(C(R_6)_2)_sN(R_6)_2$; optionally mono-substituted on nitrogen with R_6 ; and optionally mono or di-substituted on a saturated carbon with divalent radicals $-O-$ or $-O(C(R_6)_2)_sO-$;

- 20 R_6 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl of 2-7 carbon atoms, phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl,
- 25


- 80 -

thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms; with the proviso that the alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;

5 R₂, is selected from the group consisting of




- 81 -




R3 is hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms,
phenyl, carboalkyl of 2-7 carbon atoms,

5



10 R5 is hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms,
phenyl, carboalkyl of 2-7 carbon atoms,



- 82 -



R_8 , and R_9 are each, independently, $-(C(R_6)_2)_rNR_6R_6$, or $-(C(R_6)_2)_rOR_6$;

J is independently hydrogen, chlorine, fluorine, or bromine;

5 Q is alkyl of 1-6 carbon atoms or hydrogen;

$a = 0-1$;

$g = 1-6$;

$k = 0-4$;

n is $0-1$;

10 m is $0-3$;

$p = 2-4$;

$q = 0-4$;

$r = 1-4$;

$s = 1-6$;

15 $u = 0-4$ and $v = 0-4$, wherein the sum of $u+v$ is $2-4$;

or a pharmaceutically acceptable salt thereof,

provided that

when R_6 is alkenyl of 2-7 carbon atoms or alkynyl of 2-7 carbon atoms, such
alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom
through a saturated carbon atom;

and provided that

when R_3 is bound to sulfur, it cannot be hydrogen, carboxy, carboalkoxy, or
carboalkyl;

and provided that

25 when Y is $-NR_6-$ and R_7 is $-NR_6R_6$, $-N(R_6)_3$, or $-NR_6(OR_6)$, then $g = 2-6$;

when M is $-O-$ and R_7 is $-OR_6$ then $p = 1-4$;

when Y is $-NR_6-$ then $k = 2-4$;

when Y is $-O-$ and M or W is $-O-$ then $k = 1-4$


when W is not a bond with Het bonded through a nitrogen atom then $q = 2-4$

- 83 -

and when W is a bond with Het bonded through a nitrogen atom and Y is -O- or -NR₆- then k = 2-4;

and finally provided that

when A" is the moiety



5

n = 0,

Z is NH,

G₁ is hydrogen, halogen, alkyl, alkoxy, hydroxy, alkanoyloxy of 2-6 carbon atoms, or phenoxy, and

10 G₂ is hydrogen, halogen, alkyl, hydroxy, carboxyalkyl, carboalkoxyalkyl, hydroxyalkyl, alkoxy, halomethyl, carboxyl, carboalkoxy, alkanoylamino, or alkenoylamino,

then X can not be a pyridinyl, pyrimidinyl, or phenyl ring that is substituted with a hydroxy or alkoxy group.

15

13. A method of treating or inhibiting colorectal cancer in a mammal in need thereof which comprises administering to said mammal an effective amount of an NSAID and an EGFR kinase inhibitor.

20

14. The method according to claim 13, wherein the NSAID is selected from the group consisting of ibuprofen, sulindac, ketoporfén, fenoprofen, flurbiprofen, naproxen, tiaprofenic acid, suprofen, etodolac, carprofen, ketrolac, piroprofen, indoprofen, and benoxaprofen.


25

15. The method according to claim 13, wherein the EGFR kinase inhibitor irreversibly inhibits EGFR kinase.

16. The method according to Claim 13, wherein the EGFR kinase inhibitor is a compound of formula 1, having the structure

30

- 84 -



1

wherein:

X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxyethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminomethyl, N-alkylaminomethyl of 2-7 carbon atoms, N,N-dialkylaminomethyl of 3-7 carbon atoms, mercapto, methylmercapto, and benzoylamino;

Z is -NH-, -O-, -S-, or -NR-;

R is alkyl of 1-6 carbon atoms, or carboalkyl of 2-7 carbon atoms;

R₁, R₃, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyoxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9 carbon atoms, alkoxyethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms,

- 85 -

alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, 5 benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino,

10 $R_7-(C(R_6)_2)_g-Y-$, $R_7-(C(R_6)_2)_p-M-(C(R_6)_2)_k-Y-$, or $Het-W-(C(R_6)_2)_k-Y-$

Y is a divalent radical selected from the group consisting of

15 $-(CH_2)_a-$, $-O-$, and $-N-\overline{R}_6$;

R_7 is $-NR_6R_6$, or $-OR_6$;

M is $>NR_6$, $-O-$, $>N-(C(R_6)_2)_pNR_6R_6$, or $>N-(C(R_6)_2)_p-OR_6$;







W is $>NR_6$, $-O-$ or is a bond;

20 Het is a heterocycle, optionally mono- or di-substituted on carbon or nitrogen with R_6 and optionally mono-substituted on carbon with $-CH_2OR_6$; wherein the heterocycle is selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine, aziridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, 25 tetrazole, piperazine, tetrahydrofuran, and tetrahydropyran;


30 R_6 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl (2-7 carbon atoms), phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 35 1-6 carbon atoms, or alkyl of 1-6 carbon atoms;

- 86 -

R_2 , is selected from the group consisting of



- 87 -



R₅ is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6

5 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,

R₇-(C(R₆)₂)_s- , R₇-(C(R₆)₂)_p-M-(C(R₆)₂)_r-

R₈R₉-CH-M-(C(R₆)₂)_r , or Het-W-(C(R₆)₂)_r ;

R₈, and R₉ are each, independently, -(C(R₆)₂)_tNR₆R₆, or -(C(R₆)₂)_tOR₆;

10 J is independently hydrogen, chlorine, fluorine, or bromine;

Q is alkyl of 1-6 carbon atoms or hydrogen;

a = 0 or 1;

g = 1-6;

15 k = 0-4;

n is 0-1;

p = 2-4;

q = 0-4;

r = 1-4;

20 s = 1-6;

- 88 -


$u = 0\text{--}4$ and $v = 0\text{--}4$, wherein the sum of $u+v$ is 2-4;

or a pharmaceutically acceptable salt thereof.

17. . . The method according to Claim 14, wherein the EGFR kinase inhibitor
5 is N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide or a pharmaceutically
acceptable salt thereof.

18. . . The method according to Claim 15, wherein the NSAID is sulindac.

10 19. . . The method according to Claim 13, wherein the EGFR kinase inhibitor
is a compound of formula 2, having the structure



2

15

wherein:

X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one
or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or
phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be
20 optionally mono-, di-, or tri-substituted with a substituent selected from the
group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon
atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms,
halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7
carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms,
hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon
atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy,
benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to
25 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon
atoms,

- 89 -





atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino;

n is 0-1;


Y is -NH-, -O-, -S-, or -NR-;

5 R is alkyl of 1-6 carbon atoms;

R₁, R₂, R₃, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyoxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, 10 alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, 15 alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, aminoalkyl of 1-4 carbon atoms, N-alkylaminoalkyl of 2-7 carbon atoms, N,N-dialkylaminoalkyl of 20 3-14 carbon atoms, phenylamino, benzylamino,



- 90 -



- 5 R₅ is alkyl of 1-6 carbon atoms, alkyl optionally substituted with one or more halogen atoms, phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, nitro, cyano, or alkyl of 1-6 carbon atoms groups;
- R₆ is hydrogen, alkyl of 1-6 carbon atoms, or alkenyl of 2-6 carbon atoms;
- 10 R₇ is chloro or bromo
- R₈ is hydrogen, alkyl of 1-6 carbon atoms, aminoalkyl of 1-6 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-12 carbon atoms, N-cycloalkylaminoalkyl of 4-12 carbon atoms, N-cycloalkyl-N-alkylaminoalkyl of 5-18 carbon atoms, N,N-dicycloalkylaminoalkyl of 7-18 carbon atoms, morpholino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, piperidino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, N-alkyl-piperidino-N-alkyl wherein either alkyl group is 1-6 carbon atoms, azacycloalkyl-N-alkyl of 3-11 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-8 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms, chloro, fluoro, or bromo;
- Z is amino, hydroxy, alkoxy of 1-6 carbon atoms, alkylamino wherein the alkyl moiety is of 1-6 carbon atoms, dialkylamino wherein each of the alkyl moieties is of 1-6 carbon atoms, morpholino, piperazino, N-alkylpiperazino wherein the alkyl moiety is of 1-6 carbon atoms, or pyrrolidino;
- 25 m = 1-4, q = 1-3, and p = 0-3;

any of the substituents R₁, R₂, R₃, or R₄ that are located on contiguous carbon atoms can together be the divalent radical -O-C(R₈)₂-O-; or a pharmaceutically acceptable salt thereof with the proviso that when Y is -NH-, R₁, R₂, R₃, and R₄ are hydrogen, and n is 0, X is not 2-methylphenyl.

5


20. The method according to Claim 19, wherein the EGFR kinase inhibitor is (4-dimethylamino-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl]-amide or a pharmaceutically acceptable salt therof.

10

21. The method according to Claim 19, wherein the NSAID is sulindac.

22. The method according to Claim 13, wherein the EGFR kinase inhibitor is a compound of formula 3, having the structure

15



wherein:

X is a bicyclic aryl or bicyclic heteroaryl ring system of 8 to 12 atoms where the 20 bicyclic heteroaryl ring contains 1 to 4 heteroatoms selected from N, O, and S with the proviso that the bicyclic heteroaryl ring does not contain O-O, S-S, or S-O bonds and where the bicyclic aryl or bicyclic heteroaryl ring may be optionally mono-, di-, tri, or tetra-substituted with a substituent selected from the group consisting of halogen, oxo, thio, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy,

- 92 -

- carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, 5 alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalky of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino; or

- 10 X is a radical radical having the formula:



- wherein A is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono- or di-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, 15 alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalky of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 20 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino; 25

T is bonded to a carbon of A and is:

- NH(CH₂)_m -, -O(CH₂)_m -, -S(CH₂)_m -, -NR(CH₂)_m -, -(CH₂)_m -
30 -(CH₂)_mNH -, -(CH₂)_mO -, -(CH₂)_mS -, or -(CH₂)_mNR -;

L is an unsubstituted phenyl ring or a phenyl ring mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon

- 93 -

atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, 5 carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, 10 carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino; provided that L can be an unsubstituted phenyl ring only when m > 0 and T is not 15 -CH₂NH- or -CH₂O-; or

L is a 5- or 6-membered heteroaryl ring where the heteroaryl ring contains 1 to 3 heteroatoms selected from N, O, and S, with the proviso that the heteroaryl ring does not contain O-O, S-S, or S-O bonds, and where the heteroaryl ring is optionally mono- or di-substituted with a substituent selected from the group 20 consisting of halogen, oxo, thio, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, 25 benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, 30 methylmercapto, and benzoylamino;

- 94 -

Z is -NH-, -O-, -S-, or -NR- ;

R is alkyl of 1-6 carbon atoms, or carboalkyl of 2-7 carbon atoms;

G₁, G₂, R₁, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon

atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy

5 of 2-6 carbon atoms, alkynyoxy of 2-6 carbon atoms, hydroxymethyl,

halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon

atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon

atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9

carbon atoms, alkoxy of 1-6 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms,

10 alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms,

alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms,

alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon

atoms, hydroxy, trifluoromethyl, trifluoromethoxy, cyano, nitro, carboxy,

carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy,

15 phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4


carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon

atoms, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-N-alkenylamino of

4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms,

phenylamino, benzylamino,

20



R₇-(C(R₆)₂)_p-Y- , R₇-(C(R₆)₂)_p-M-(C(R₆)₂)_k-Y- , or Het-(C(R₆)₂)_q-W-(C(R₆)₂)_k-Y- ;

25 or R₁ and R₄ are as defined above and G₁ or G₂ or both are

R₂-NH— ;

or if any of the substituents R₁, G₂, G₃, or R₄ are located on contiguous

carbon atoms then they may be taken together as the divalent radical

-O-C(R₆)₂-O-;

30 Y is a divalent radical selected from the group consisting of

- 95 -

$-(CH_2)_a-$, $-O-$, and $-N_{R_6}-$;


R₇ is -NR₆R₆, -OR₆, -J, -N(R₆)₃⁺, or -NR₆(OR₆);

5

M is $>\text{NR}_6$, $-\text{O}-$, $>\text{N}-(\text{C}(\text{R}_6)_2)_p\text{NR}_6\text{R}_6$, or $>\text{N}-(\text{C}(\text{R}_6)_2)_p-\text{OR}_6$;

W is $>\text{NR}_6$, -O- or is a bond;

Het is selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine, aziridine, pyridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, thiazole, thiazolidine, tetrazole, piperazine, furan, thiophene, tetrahydrothiophene,




tetrahydrofuran, dioxane, 1,3-dioxolane, tetrahydropyran, and
 wherein Het is optionally mono- or di-substituted on carbon or nitrogen with
 R_6 , optionally mono- or di-substituted on carbon with hydroxy, $-N(R_6)_2$, or
 $-OR_6$, optionally mono or di-substituted on carbon with the mono-valent
 radicals $-(C(R_6)_2)_sOR_6$ or $-(C(R_6)_2)_sN(R_6)_2$, and optionally mono or di-
 substituted on a saturated carbon with divalent radicals $-O-$ or $-O(C(R_6)_2)_sO-$;

R₆ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl (2-7 carbon atoms), phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms; with the proviso that the


- 96 -

alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;


R₂, is selected from the group consisting of



- 97 -




5 R₃ is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,



10

R₅ is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,



$R_7-(C(R_6)_2)_s-$, $R_7-(C(R_6)_2)_p-M-(C(R_6)_2)_r-$,

$R_8R_9-CH-M-(C(R_6)_2)_r-$, or $Het-(C(R_6)_2)_q-W-(C(R_6)_2)_r-$;

R_8 , and R_9 are each, independently, $-(C(R_6)_2)_rNR_6R_6$, or $-(C(R_6)_2)_rOR_6$;

5

J is independently hydrogen, chlorine, fluorine, or bromine;

Q is alkyl of 1-6 carbon atoms or hydrogen;

$a = 0$ or 1 ;

$g = 1-6$;

10 $k = 0-4$;

n is $0-1$;

m is $0-3$;

$p = 2-4$;

$q = 0-4$;

15 $r = 1-4$;

$s = 1-6$;

$u = 0-4$ and $v = 0-4$, wherein the sum of $u+v$ is $2-4$;

or a pharmaceutically acceptable salt thereof,

provided that

20 when R_6 is alkenyl of 2-7 carbon atoms or alkynyl of 2-7 carbon atoms, such

alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom
through a saturated carbon atom;

and further provided that

when Y is $-NR_6-$ and R_7 is $-NR_6R_6$, $-N(R_6)_3^+$, or $-NR_6(OR_6)$, then $g = 2-6$;

25 when M is $-O-$ and R_7 is $-OR_6$ then $p = 1-4$;

when Y is $-NR_6-$ then $k = 2-4$;


when Y is $-O-$ and M or W is $-O-$ then $k = 1-4$

when W is not a bond with Het bonded through a nitrogen atom then $q = 2-4$

- 99 -

and when W is a bond with Het bonded through a nitrogen atom and Y is -O- or -NR₆- then k = 2-4.

23. The method according to Claim 13, wherein the EGFR kinase inhibitor
5 is a compound of formula 4, having the structure



wherein:

- 10 X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino;

- 100 -

Z is -NH-, -O-, -S-, or -NR- ;


R is alkyl of 1-6 carbon atoms, or carboalkyl of 2-7 carbon atoms;

G₁, G₂, R₁, and R₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy

5 of 2-6 carbon atoms, alkynyoxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 1-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9

10 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, trifluoromethoxy, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-N-alkenylamino of 15 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino,


16



R₇-(C(R₆)₂)_q-Y- . R₇-(C(R₆)₂)_p-M-(C(R₆)₂)_k-Y- , or Het-(C(R₆)₂)_q-W-(C(R₆)₂)_k-Y-

with the proviso that either G₁ or G₂ or both G₁ and G₂ must be a radical selected from the group

- 101 -



$R'_7-(C(R_6)_2)_q-Y-$, $R_7-(C(R_6)_2)_p-M-(C(R_6)_2)_k-Y-$, $Het-(C(R_6)_2)_q-W-(C(R_6)_2)_k-Y-$,

or $R_2-\overset{H}{N}-$;

Y is a divalent radical selected from the group consisting of

$-(CH_2)_a-$, $-O-$, and $-N_{R_6}-$;

5

R_7 is $-NR_6R_6$, $-J$, $-OR_6$, $-N(R_6)_3^+$, or $-NR_6(OR_6)$;

R'_7 is $-NR_6(OR_6)$, $-N(R_6)_3^+$, alkenoxy of 1-6 carbon atoms, alkynoxy of 1-6 carbon


atoms, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, N-alkyl-N-alkynylamino of 4 to 12 carbon atoms, N-

10 alkenyl-N-alkynylamino of 4 to 12 carbon atoms, or N,N-dialkynylamino of 6-12 carbon atoms with the proviso that the alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;

M is $>NR_6$, $-O-$, $>N-(C(R_6)_2)_pNR_6R_6$, or $>N-(C(R_6)_2)_p-OR_6$;

W is $>NR_6$, $-O-$ or is a bond;

15 Het is a heterocycle selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine, aziridine, pyridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, thiazole, thiazolidine, tetrazole, piperazine, furan, thiophene, tetrahydrothiophene, tetrahydrofuran, dioxane, 1,3-dioxolane, tetrahydro-



20

wherein the heterocycle is optionally mono- or di-substituted on carbon or nitrogen with R_6 , optionally mono- or di-substituted on carbon with hydroxy,

- 102 -

-N(R₆)₂, or -OR₆, optionally mono or di-substituted on carbon with the mono-valent radicals -(C(R₆)₂)_sOR₆ or -(C(R₆)₂)_sN(R₆)₂, or optionally mono or di-substituted on a saturated carbon with divalent radicals -O- or -O(C(R₆)₂)_sO-;


5

R₆ is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl (2-7 carbon atoms), phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms;







10

15

R₂, is selected from the group consisting of




- 103 -



5

R3 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,


- 104 -



$\text{R}_7\text{-(C(R}_6\text{)}_2\text{)}_{\text{s}}\text{-} \quad , \quad \text{R}_7\text{-(C(R}_6\text{)}_2\text{)}_{\text{p}}\text{-M-(C(R}_6\text{)}_2\text{)}_{\text{r}}\text{-}$

$\text{R}_8\text{R}_9\text{-CH-M-(C(R}_6\text{)}_2\text{)}_{\text{r}}\text{-} \quad , \quad \text{or Het-(C(R}_6\text{)}_2\text{)}_{\text{q}}\text{-W-(C(R}_6\text{)}_2\text{)}_{\text{r}}\text{-} \quad ;$

with the proviso that at least one of the R_3 groups is selected from the group




$\text{R}'_7\text{-(C(R}_6\text{)}_2\text{)}_{\text{s}}\text{-} \quad , \quad \text{R}_7\text{-(C(R}_6\text{)}_2\text{)}_{\text{p}}\text{-M-(C(R}_6\text{)}_2\text{)}_{\text{r}}\text{-}$

$\text{R}_8\text{R}_9\text{-CH-M-(C(R}_6\text{)}_2\text{)}_{\text{r}}\text{-} \quad , \quad \text{or Het-(C(R}_6\text{)}_2\text{)}_{\text{q}}\text{-W-(C(R}_6\text{)}_2\text{)}_{\text{r}}\text{-} \quad ;$

5

R_5 is independently hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,



$\text{R}_7\text{-(C(R}_6\text{)}_2\text{)}_{\text{s}}\text{-} \quad , \quad \text{R}_7\text{-(C(R}_6\text{)}_2\text{)}_{\text{p}}\text{-M-(C(R}_6\text{)}_2\text{)}_{\text{r}}\text{-}$

10 $\text{R}_8\text{R}_9\text{-CH-M-(C(R}_6\text{)}_2\text{)}_{\text{r}}\text{-} \quad , \quad \text{or Het-(C(R}_6\text{)}_2\text{)}_{\text{q}}\text{-W-(C(R}_6\text{)}_2\text{)}_{\text{r}}\text{-} \quad ;$

R_8 , and R_9 are each, independently, $-(\text{C(R}_6\text{)}_2\text{)}_{\text{r}}\text{NR}_6\text{R}_6$, or $-(\text{C(R}_6\text{)}_2\text{)}_{\text{r}}\text{OR}_6$;

15 J is independently hydrogen, chlorine, fluorine, or bromine;

Q is alkyl of 1-6 carbon atoms or hydrogen;


$\text{a} = 0$ or 1;

- 105 -

- g = 1-6;
k = 0-4;
n is 0-1;
p = 2-4;
- 5 q=0-4;
r = 1-4;
s = 1-6;
u = 0-4 and v = 0-4 , wherein the sum of u+v is 2-4;
or a pharmaceutically acceptable salt thereof,
- 10 provided that
when R₆ is alkenyl of 2-7 carbon atoms or alkynyl of 2-7 carbon atoms, such alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;
- and further provided that
- 15 when Y is -NR₆- and R₇ is -NR₆R₆, -N(R₆)₃⁺, or -NR₆(OR₆), then g = 2-6;
when M is -O- and R₇ is -OR₆, then p = 1-4;
when Y is -NR₆-, then k = 2-4;
when Y is -O- and M or W is -O-, then k = 1-4
when W is not a bond with Het bonded through a nitrogen atom, then q = 2-4
- 20 and when W is a bond with Het bonded through a nitrogen atom and Y is -O- or -NR₆-, then k = 2-4.

24. The method according to Claim 13, wherein the EGFR kinase inhibitor is a compound of formula 5, having the structure

25



- 106 -

wherein:

X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or

X is pyridinyl, pyrimidinyl, or Ph; or

- 5 X is a bicyclic aryl or bicyclic heteroaryl ring system of 8 to 12 atoms, where the bicyclic heteroaryl ring contains 1 to 4 heteroatoms selected from N, O, and S; wherein the bicyclic aryl or bicyclic heteroaryl ring may be optionally mono-, di-, tri-, or tetra-substituted with a substituent selected from the group consisting of halogen, oxo, thio, alkyl of 1-6 carbon atoms, alkenyl of 2-6
10 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy,
15 benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon
20 atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino; or

X is the radical $\text{E}-\text{T}'-\text{L}$;

E is pyridinyl, pyrimidinyl, or Ph;

- 25 T is substituted on E at carbon and is

- NH(CH₂)_m-, -O(CH₂)_m-, -S(CH₂)_m-, -NR(CH₂)_m-, -(CH₂)_m-
-(CH₂)_mNH-, - (CH₂)_mO-, - (CH₂)_mS-, or - (CH₂)_mNR-;

L is a Ph; or

- 25 L is a 5- or 6-membered heteroaryl ring where the heteroaryl ring contains 1 to 3
30 heteroatoms selected from N, O, and S; wherein the heteroaryl ring may be optionally mono- or di-substituted with a substituent selected from the group consisting of halogen, oxo, thio, alkyl of 1-6 carbon atoms, alkenyl of 2-6

- 107 -

carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxyethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, 5 benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon 10 atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino;




Pyridinyl, pyrimidinyl, or Ph are pyridinyl, pyrimidinyl, or phenyl radicals, 15 respectively, which may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxyethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, benzoyl, 20 amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, alkanoylamino of 1-6 carbon atoms, alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, carboxyalkyl of 2-7 carbon atoms, carboalkoxyalkyl of 3-8 carbon atoms, aminoalkyl of 1-5 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-10 carbon atoms, N-alkylaminoalkoxy of 2-9 carbon atoms, N,N-dialkylaminoalkoxy of 25 3-10 carbon atoms, mercapto, methylmercapto, and benzoylamino;

Z is -NH-, -O-, -S-, or -NR-;

30 R is alkyl of 1-6 carbon atoms, or carboalkyl of 2-7 carbon atoms;

A" is a diivalent moiety selected from the group

- 108 -



- G₁, G₂, G₃, and G₄ are each, independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, alkenyloxy of 2-6 carbon atoms, alkynyoxy of 2-6 carbon atoms, hydroxymethyl, halomethyl, alkanoyloxy of 2-6 carbon atoms, alkenoyloxy of 3-8 carbon atoms, alkynoyloxy of 3-8 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkenoyloxymethyl of 4-9 carbon atoms, alkynoyloxymethyl of 4-9 carbon atoms, alkoxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, alkylsulphinyl of 1-6 carbon atoms, alkylsulphonyl of 1-6 carbon atoms, alkylsulfonamido of 1-6 carbon atoms, alkenylsulfonamido of 2-6 carbon atoms, alkynylsulfonamido of 2-6 carbon atoms, hydroxy, trifluoromethyl, trifluoromethoxy, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino of 1-4 carbon atoms, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-alkyl-N-alkenylamino of 4 to 12 carbon atoms, N,N-dialkenylamino of 6-12 carbon atoms, phenylamino, benzylamino, R₂NH,
- R₇-(C(R₆)₂)_p-N_{(C(R_6)_2)_p}-(C(R₆)₂)_k-Y- R₈R₉-CH-M-(C(R₆)₂)_k-Y- . . .
- R₇-(C(R₆)₂)_g-Y- , R₇-(C(R₆)₂)_p-M-(C(R₆)₂)_k-Y- , Het-(C(R₆)₂)_q-W-(C(R₆)₂)_k-Y- . . .
- with the proviso that G₃ and G₄ are not R₂NH;
- Y is a divalent radical selected from the group consisting of

- 109 -

$-\text{S}-$, $-(\text{CH}_2)_a-$, $-\text{O}-$, and $-\text{N}^{\text{R}_6}$;


R_7 is $-\text{NR}_6\text{R}_6$, $-\text{OR}_6$, $-\text{J}$, $-\text{N}(\text{R}_6)_3$, or $-\text{NR}_6(\text{OR}_6)$;

M is $>\text{NR}_6$, $-\text{O}-$, $>\text{N}-(\text{C}(\text{R}_6)_2)_p\text{NR}_6\text{R}_6$, or $>\text{N}-(\text{C}(\text{R}_6)_2)_p-\text{OR}_6$;

W is $>\text{NR}_6$, $-\text{O}-$ or is a bond;

- 5 Het is a heterocyclic radical selected from the group consisting of morpholine, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S,S-dioxide, piperidine, pyrrolidine, aziridine, pyridine, imidazole, 1,2,3-triazole, 1,2,4-triazole, thiazole, thiazolidine, tetrazole, piperazine, furan, thiophene, tetrahydrothiophene, tetrahydrofuran, dioxane, 1,3-dioxolane, tetrahydro-


10 pyran, and




- which may be optionally mono- or di-substituted on carbon with R_6 , hydroxy, $-\text{N}(\text{R}_6)_2$, $-\text{OR}_6$, $-(\text{C}(\text{R}_6)_2)_p\text{OR}_6$ or $-(\text{C}(\text{R}_6)_2)_p\text{N}(\text{R}_6)_2$; optionally mono-substituted on nitrogen with R_6 ; and optionally mono or di-substituted on a saturated carbon with divalent radicals $-\text{O}-$ or $-\text{O}(\text{C}(\text{R}_6)_2)_p\text{O}-$;

- 15 R_6 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 1-6 carbon atoms, carboalkyl of 2-7 carbon atoms, carboxyalkyl of 2-7 carbon atoms, phenyl, or phenyl optionally substituted with one or more halogen, alkoxy of 1-6 carbon atoms, trifluoromethyl, amino, alkylamino of 1-3 carbon atoms, dialkylamino of 2-6 carbon atoms, nitro, cyano, azido, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, carboxyl, carboalkoxy of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms; with the proviso that the alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom through a saturated carbon atom;
- 20 25 R_2 is selected from the group consisting of


- 110 -



- 111 -



R3 is hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms,





5



R5 is hydrogen, alkyl of 1-6 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms,

10 phenyl, carboalkyl of 2-7 carbon atoms,



- 112 -

R₈, and R₉ are each, independently, -(C(R₆)₂)_rNR₆R₆, or -(C(R₆)₂)_rOR₆;

J is independently hydrogen, chlorine, fluorine, or bromine;

Q is alkyl of 1-6 carbon atoms or hydrogen;

5 a = 0-1;

g = 1-6;

k = 0-4;

n is 0-1;

m is 0-3;

10 p = 2-4;

q = 0-4;

r = 1-4;

s = 1-6;

u = 0-4 and v = 0-4, wherein the sum of u+v is 2-4;

15 or a pharmaceutically acceptable salt thereof,

provided that

when R₆ is alkenyl of 2-7 carbon atoms or alkynyl of 2-7 carbon atoms, such
alkenyl or alkynyl moiety is bound to a nitrogen or oxygen atom
through a saturated carbon atom;

20 and provided that

when R₃ is bound to sulfur, it cannot be hydrogen, carboxy, carboalkoxy, or
carboalkyl;

and provided that

when Y is -NR₆- and R₇ is -NR₆R₆, -N(R₆)₃, or -NR₆(OR₆), then g = 2-6;

25 when M is -O- and R₇ is -OR₆ then p = 1-4;

when Y is -NR₆- then k = 2-4;

when Y is -O- and M or W is -O- then k = 1-4

when W is not a bond with Het bonded through a nitrogen atom then q = 2-4


and when W is a bond with Het bonded through a nitrogen atom and Y is -O-

30 or -NR₆- then k = 2-4;

and finally provided that

when A" is the moiety

- 113 -



$n = 0$,

Z is NH,

G₁ is hydrogen, halogen, alkyl, alkoxy, hydroxy, alkanoyloxy of 2-6 carbon atoms, or phenoxy, and

G₂ is hydrogen, halogen, alkyl, hydroxy, carboxyalkyl, carboalkoxyalkyl, hydroxyalkyl, alkoxy, halomethyl, carboxyl, carboalkoxy, alkanoylamino, or alkenoylamino,

then X can not be a pyridinyl, pyrimidinyl, or phenyl ring that is substituted with a hydroxy or alkoxy group.

25. Use of a combination of an NSAID and an EGFR kinase inhibitor for the preparation of a medicament for the treatment or inhibition of colonic polyps or colorectal cancer in a mammal in need thereof.

15

26. Use of a combination of an NSAID and an EGFR kinase inhibitor according to Claim 25, wherein the NSAID is selected from those listed in claim 2.

27. Use of a combination of an NSAID and an EGFR kinase inhibitor according to Claim 25, wherein the EGFR kinase inhibitor irreversibly inhibits EGFR kinase.

28. Use of a combination of an NSAID and an EGFR kinase inhibitor according to Claim 25, wherein the EGFR kinase inhibitor is as defined in claim 4.

25

29. Use of a combination of an NSAID and an EGFR kinase inhibitor according to Claim 28, wherein the EGFR kinase inhibitor is as defined in claim 5.

- 114 -

30. Use of a combination of an NSAID and an EGFR kinase inhibitor according to Claim 29, wherein the NSAID is sulindac.

31. Use of a combination of an NSAID and an EGFR kinase inhibitor
5 according to Claim 25, wherein the EGFR kinase inhibitor is as defined in claim 7.

32. Use of a combination of an NSAID and an EGFR kinase inhibitor according to Claim 31, wherein the EGFR kinase inhibitor is as defined in claim 8.

10 33. Use of a combination of an NSAID and an EGFR kinase inhibitor according to Claim 32, wherein the NSAID is sulindac.

34. Use of a combination of an NSAID and an EGFR kinase inhibitor according to Claim 25, wherein the EGFR kinase inhibitor is as defined in claim 10.

15 35. Use of a combination of an NSAID and an EGFR kinase inhibitor according to Claim 25, wherein the EGFR kinase inhibitor is as defined in claim 11.

20 36. Use of a combination of an NSAID and an EGFR kinase inhibitor according to Claim 25, wherein the EGFR kinase inhibitor is as defined in claim 12.

37. Use of an NSAID and an EGFR kinase inhibitor for the preparation of a medicament for the treatment or inhibition of colonic polyps or colorectal cancer in a mammal in need thereof.

25 38. Use of an NSAID and an EGFR kinase inhibitor according to Claim 37, wherein the NSAID is selected from those listed in claim 2.

39. Use of an NSAID and an EGFR kinase inhibitor according to
30 Claim 37, wherein the EGFR kinase inhibitor irreversibly inhibits EGFR kinase.

40. Use of an NSAID and an EGFR kinase inhibitor according to Claim 37, wherein the EGFR kinase inhibitor is as defined in claim 4.

- 115 -

41. Use of an NSAID and an EGFR kinase inhibitor according to
Claim 40, wherein the EGFR kinase inhibitor is as defined in claim 5.

42. Use of an NSAID and an EGFR kinase inhibitor according to
5 Claim 41, wherein the NSAID is sulindac.

43. Use of an NSAID and an EGFR kinase inhibitor according to
Claim 37, wherein the EGFR kinase inhibitor is as defined in claim 7.

10 44. Use of an NSAID and an EGFR kinase inhibitor according to
Claim 43, wherein the EGFR kinase inhibitor is as defined in claim 8.

45. Use of an NSAID and an EGFR kinase inhibitor according to
Claim 44, wherein the NSAID is sulindac.

15 46. Use of an NSAID and an EGFR kinase inhibitor according to
Claim 37, wherein the EGFR kinase inhibitor is as defined in claim 10.

20 47. Use of an NSAID and an EGFR kinase inhibitor according to
Claim 37, wherein the EGFR kinase inhibitor is as defined in claim 11.

48. Use of an NSAID and an EGFR kinase inhibitor according to
Claim 37, wherein the EGFR kinase inhibitor is as defined in claim 12.

25 49. A pharmaceutical composition for use as a medicament comprising a
combination of (a) an NSAID and (b) an EGFR kinase inhibitor.

50. A pharmaceutical composition as claimed in claims 25 or 37 or 49 also
comprising a pharmaceutically acceptable carrier.

30 51. A product comprising an NSAID and an EGFR kinase inhibitor as a
combined preparation for simultaneous, separate or sequential use in the treatment or
inhibition of colonic polyps or colorectal cancer.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/21021

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K45/06 A61K31/505 A61K31/47 // (A61K31/505, 31:19), (A61K31/47, 31:19)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EMBASE, BIOSIS, CANCERLIT, PAJ, WPI Data, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT
--

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KELLOFF, GARY J. ET AL: "New agents for cancer chemoprevention" J. CELL. BIOCHEM. (1997), VOLUME DATE 1996, (SUPPL. 26), 1-28 , XP000676752 page 3, column 2, paragraph 4 page 4, column 1, paragraph 4 -column 2, paragraph 1 page 14, column 2, paragraph 1 ---	1-51
A	WO 99 23077 A (MARFAT ANTHONY ;PFIZER PROD INC (US)) 14 May 1999 (1999-05-14) page 9, line 29-40 page 156, line 35-39 ---	1-52
A	WO 99 24037 A (AMERICAN CYANAMID CO) 20 May 1999 (1999-05-20) abstract -----	1-52

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

• Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
---	--

12 January 2001

18/01/2001

Name and mailing address of the ISA	Authorized officer
-------------------------------------	--------------------

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Leherte, C

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-51

Present claims 1-51 relate to compounds defined by reference to desirable characteristics or properties, namely "NSAID" and "EGFR kinase inhibitors" of varying formulas.

The claims cover all compounds having those characteristics or properties, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds individually structurally identified by name in the claims, with due regard to the therapeutic applications mentioned in the claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. No.

PCT/US 00/21021

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9923077 A	14-05-1999	AU	9455298 A		24-05-1999
		BR	9813926 A		19-09-2000
		EP	1028946 A		23-08-2000
		NO	20002129 A		03-07-2000
WO 9924037 A	20-05-1999	AU	1308799 A		31-05-1999
		BR	9814116 A		03-10-2000
		EP	1039910 A		04-10-2000
		NO	20002166 A		28-06-2000